The kynurenine pathway in cognition, dementia, and aging by Solvang, Stein-Erik Hafstad
Stein-Erik Hafstad Solvang
The kynurenine pathway in
cognition, dementia, and aging
2021
Thesis for the degree of Philosophiae Doctor (PhD)
University of Bergen, Norway
at the University of Bergen
Avhandling for graden philosophiae doctor (ph.d )
ved Universitetet i ergen
.
2017
Dato for disputas: 1111
Stein-Erik Hafstad Solvang
The kynurenine pathway in
cognition, dementia, and aging
Thesis for the de ree of P il i  Doctor (PhD)
Date of defense: 16.06.2021
The material in this publication is covered by the provisions of the Copyright Act.
Print:     Skipnes Kommunikasjon / University of Bergen
© Copyright Stein-Erik Hafstad Solvang
Name:        Stein-Erik Hafstad Solvang
Title: The kynurenine pathway in cognition, dementia, and aging


























This research project was performed at the Department of Internal Medicine at 
Haraldsplass Deaconess Hospital (HDS), Bergen, Norway. There have been weekly 
meetings at HDS with my main supervisor, Lasse Melvær Giil, focused on planning 
studies, statistical analysis, and scientific writing. I have also had frequent meetings 
with my co-supervisors and these discussions have been a source of inspiration. My 
co-supervisor, professor emeritus Jan Erik Nordrehaug, has made this project possible 
through his expertise and vast experience. My co-supervisor, professor emeritus 
Grethe S. Tell, has contributed much-needed expertise concerning The Hordaland 
Health Study (HUSK) and epidemiological research. In addition, I have gained 
knowledge, inspiration, and support from discussions with my fellow researchers and 
colleagues at HDS. Measurements of kynurenines in serum, plasma, and cerebrospinal 
fluid and sample handling were facilitated by Bevital AS. Professor emeritus Per 
Magne Ueland and his laboratory have provided substantial biochemical expertise to 
conduct these studies, relying on their extensive experience of measuring and studying 
the metabolites of the kynurenine pathway. This work would not have been possible 
without both national and international collaboration from the COGNORM, the 
Dementia Study of Western Norway (DemVest), HUSK, the Melbourne Collaborative 
Cohort Study (MCCS), and the Western Norway B Vitamin Intervention Trial 
(WENBIT).  
Funded by 








The kynurenine pathway catabolizes the essential amino acid tryptophan and has been 
studied since the early part of the 20th century. The neurobiology of the kynurenine 
pathway was not extensively studied for years as scientists viewed brain tryptophan 
metabolism mostly through the lens of serotonin. In recent years, research efforts have 
focused on the ability of kynurenines to influence neurotransmitter systems and 
modulate the immune system. Essential organs and tissues, including the liver, 
immune cells, brain, muscle, and the gastrointestinal tract, express the kynurenine 
pathway's enzymes. Indeed, the kynurenine pathway, induced by inflammatory 
cytokines, is now implicated in metabolic, cardiovascular, gastrointestinal, psychiatric, 
and neurological disorders. Despite significant experimental evidence linking the 
kynurenines to cognition, dementia, and aging, there is a lack of rigorous clinical 
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Rs  –  Spearman’s Rho 
SD  –  Standard deviation 
TDO  –  Tryptophan 2, 3 dioxygenase 
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Background: Experimental studies implicate the kynurenine pathway in cognitive 
function, dementia, aging, and longevity. Comparatively, clinical studies are few and 
most lack comprehensive targeted metabolomic profiling of the kynurenine pathway.  
Aims: To investigate associations between circulating kynurenines and cognitive 
function in older adults (Study I) and between kynurenines, cognitive and 
neuropsychiatric prognosis in mild dementia (Study II). Lastly, to assess the 
relationship between aging and concentrations of metabolites of the kynurenine 
pathway in blood and cerebrospinal fluid (CSF) using longitudinal cohorts (Study III). 
Methods: Tryptophan (Trp) and nine kynurenines were measured in serum, plasma 
and cerebrospinal fluid. Associations between the kynurenines and cognitive 
performance were estimated using Zellner’s regression in community-dwelling older 
adults (Study I, n = 2174), and between the kynurenines, cognitive performance and 
neuropsychiatric symptoms in patients with mild dementia using a multilevel model 
(Study II, n = 155). In Study III, associations between age and the kynurenines were 
investigated in multilevel models in two longitudinal studies (n = 970 and n = 604), 
and non-parametrically in a small cohort with CSF samples (n = 109). Associations 
between the kynurenines and frailty were assessed using regression, mortality using 
Cox regression, and minor age differences using a multinomial logit model. The 
results of studies I and II were adjusted for multiple comparisons. 
Main findings: Higher kynurenine to tryptophan ratio (KTR) and neopterin 
concentrations were linearly associated with lower cognitive test performance, 
whereas kynurenine (Kyn) had a non-linear, quadratic association with cognitive test 
performance (Study I). The quadratic association between cognitive test performance 
and Kyn was also present in mild dementia, where higher kynurenic acid to 
kynurenine ratio (KKR) was further associated with more neuropsychiatric symptoms 
over time (Study II). In Study III, the strongest associations between age and the 
kynurenines were with Kyn, quinolinic acid (QA), and KTR which were positively 




with age and decreased over time. Kyn, 3-hydroxykynurenine, kynurenic acid, 3-
hydroxyanthranilic acid, QA and KTR were associated with frailty. Higher Trp 
concentrations were associated with lower all-cause mortality, whereas higher QA and 
KTR concentrations were associated with higher all-cause mortality in two cohorts of 
community-dwelling adults. Kyn and QA increased in the CSF over a period of four 
years and correlated the most with age. Compared to serum concentrations, age was 
more strongly correlated to CSF concentrations of Kyn and particularly QA.  
Conclusions: We found a non-linear relationship between Kyn and cognitive 
performance in both community-dwelling older adults and patients with mild 
dementia, where higher and lower Kyn concentrations were associated with poorer 
cognitive performance. Further, it appears that activation of the kynurenine pathway, 
reflected by increased KTR, is associated with poorer cognitive performance, aging, 
frailty, and mortality. However, of the downstream kynurenines, QA showed the 
strongest association with aging, frailty, and mortality and was more strongly 
correlated with age in the CSF relative to serum over time. Accordingly, the aging 
brain could be exposed to a disproportionate increase in the excitotoxic QA. Higher 
KKR, which may reflect increased kynurenine aminotransferase activity, was 
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Tryptophan (Trp) is mainly metabolized by the kynurenine pathway with minor 
quantities used to generate serotonin and melatonin. The metabolites of the kynurenine 
pathway are collectively referred to as the kynurenines. They are involved in 
antioxidant activity, inflammation, immune regulation, and neurotransmission. 
Significantly, the kynurenine pathway provides the substrate for nicotinamide adenine 
dinucleotide (NAD+, or vitamin B3) synthesis, a central cofactor of cellular 
metabolism. 1 Experimental studies have implicated the kynurenine pathway in 
cognitive function, neurodegeneration, aging, and longevity. 2-6 In contrast, clinical 
studies are relatively few and have often relied on measuring a few select metabolites 
of the kynurenine pathway. This thesis aims to fill some of the knowledge gaps 
outlined below by using comprehensive targeted metabolomic profiling of the 
kynurenine pathway using data from several cohort studies.  
AN OVERVIEW OF KYNURENINE METABOLITES 
Tryptophan Metabolism 
Trp is an essential amino acid obtained through meat, dairy products, and fruit. 7 Once 
ingested, Trp is absorbed in the gut, passes into the portal circulation, and reaches the 
tissues by way of the liver. 1 However, gut microbiota can metabolize Trp to 
tryptamine, serotonin, kynurenines, and indoles prior to absorption. 7 Trp and the 
kynurenines can, in turn, influence the enteric nervous system and intestinal motility. 8 
Under physiological conditions, the liver degrades around 90% of Trp. Cells take up 
circulating Trp for synthesis and turnover of proteins. Intracellular proteolysis and 
protein catabolism partly regenerate Trp for subsequent protein synthesis. 7   
Expression of Kynurenine Pathway Enzymes 
The enzymes that catalyze the chemical reactions of the kynurenine pathway are 
differentially expressed in organs, tissues, and cells. 9 In humans, the enzymes are 




endothelial cells. 9 In the brain, there is a differential expression of enzymes in 
astrocytes compared to microglia. 10 The kynurenine pathway has two rate-limiting 
enzymes: indoleamine 2, 3 dioxygenase (IDO) and tryptophan 2, 3 dioxygenase 
(TDO). Both catalyze the conversion of Trp to kynurenine (Kyn). TDO is mainly 
expressed in the liver. 11 Compared to TDO, IDO has wider tissue distribution, 
including cells of the immune system, most significantly antigen-presenting cells such 
as macrophages and dendritic cells. 12 Further, IDO is expressed in the lung, intestine, 
placenta, kidney, liver, and brain. 9 Skeletal muscle also metabolizes Trp through the 
kynurenine pathway. 1 The contribution of extrahepatic Trp metabolism along the 
kynurenine pathway is relatively minor (5-10%) under physiological conditions. 
However, this becomes more significant following activation of the immune system. 13  
THE BIOCHEMISTRY OF THE KYNURENINE PATHWAY 
Rate-Limiting Enzymes 
IDO and TDO are members of the heme-dependent family of enzymes. Specifically, 
the heme dioxygenase enzymes which uniquely use heme for catalysis. 14 The 
enzymes are functionally very similar but structurally different and are thus considered 
autologous enzymes. IDO and TDO have likely evolved independently, as gene 
duplication has not been identified. 15 Several IDO homologs have been identified in 
different species, but IDO1 and IDO2 are the main homologs expressed in humans. 9 
These homologs are encoded on genes adjacent to each other, suggesting that the 
homologs arose from gene duplication. 16 
Metabolism of Tryptophan by the Kynurenine Pathway 
The kynurenine pathway degrades Trp by several enzymatic reactions to quinolinic 
acid (QA). 11 Briefly, the metabolic pathway that gives rise to QA starts with the 
formation of Kyn from Trp by way of the intermediate metabolite N-
formylkynurenine. Next, Kyn gives rise to 3-hydroxykynurenine (HK), which is 




semialdehyde (ACMS) is generated from HAA by the oxidoreductase enzyme 3-
hydroxyanthranilic acid 3,4-dioxygenase (3-HAO), and subsequently converted to 
either picolinic acid (PIC), or QA. For conceptual purposes, the kynurenine pathway 
can be divided into the main pathway and branches from the main pathway, where 
Kyn and HK give rise to kynurenic acid (KA), anthranilic acid (AA), and xanthurenic 
acid (XA). Figure 1 on the next page shows a summary of the kynurenine pathway.  
In the main pathway, the first step of the kynurenine pathway is the oxidation of 
Trp to N-formylkynurenine by either IDO or TDO. 17 Kynurenine formamidase, a 
hydroxylase, catalyzes the hydrolysis of N-formylkynurenine to Kyn, 18 a pivotal 
metabolite of the kynurenine pathway. Kynurenine 3-monooxygenase (KMO), an 
oxidoreductase, catalyzes the conversion of Kyn to HK using oxygen and nicotinamide 
adenine dinucleotide phosphate (NADPH). 19 Kynureninase (KYNU), belonging to the 
family of aminoreductases, catalyzes the conversion of HK to HAA. 20                         
3-HAO catalyzes the conversion of HAA and O2 to ACMS. In the main pathway, 
ACMS is spontaneously converted to QA.  10  However, α-amino-ß-carboxymuconate-
ε-semialdehyde decarboxylase (ACMSD), a zinc-dependent amidohydrolase, 21 
preferentially catalyzes the conversion of ACMS to PIC. Saturation of ACMSD shifts 
the conversion of ACMS towards QA. 22 Quinolinate phosphoribosyl transferase 
(QPRT) is a glycosyltransferase enzyme that catalyzes the formation of nicotinic acid 
mononucleotide from QA and 5-phosphoribosyl-1-pyrophosphate, fueling NAD+ 
synthesis. 10  
There are primarily three important branches; First, Kyn can be metabolized to 
KA, by four kynurenine aminotransferases (KATs). 23 Second, KYNU can convert 







Figure 1. The Kynurenine Pathway. Trp is oxidized to N-formylkynurenine by the rate-limiting enzymes 
indoleamine 2, 3 dioxygenase (IDO) or tryptophan 2, 3 dioxygenase (TDO). Formamidase catalyzes the 
formation of Kyn from N-formylkynurenine. Kynurenine 3-monooxygenase (KMO) metabolizes Kyn to 
HK, which is converted to HAA by kynureninase (KYNU). ACMS is formed from HAA, catalyzed by 3-
hydroxyanthranilic acid 3,4-dioxygenase (3-HAO). ACMS converts spontaneously to QA, which is 
further metabolized by the action of quinolinate phosphoribosyl transferase (QPRT) and several 
intermediary steps to nicotinamide adenine dinucleotide (NAD+). AA is produced from Kyn by KYNU. 
Kynurenine aminotransferases (KATs) generate KA from Kyn and XA from HK. α-amino-ß-
carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) converts ACMS to the intermediary 
metabolite 2-aminomuconic-6-semialdehyde (not shown), which is spontaneously converted to picolinic 




Regulators of Enzyme Activity in the Kynurenine Pathway 
Tryptophan Availability 
Under physiological conditions, the activity of the kynurenine pathway is mostly 
determined by plasma free Trp. Generally, 90-95% of Trp in the bloodstream is bound 
to albumin, with 5-10% in an unbound state. While Trp induces TDO, Kyn acts as an 
allosteric inhibitor, resulting in a negative feedback loop. 9 
Glucocorticosteroids 
Glucocorticosteroids increase in response to physiological stressors 24 and induce TDO 
expression by acting on glucocorticoid-responsive elements of the TDO gene. 25 
Pro-Inflammatory Cytokines 
Cytokines can be broadly classified as pro-inflammatory or anti-inflammatory. IDO is 
mainly activated by the pro-inflammatory cytokine interferon-γ (IFN- γ). 26 However, 
other pro-inflammatory cytokines such as interferon-α, 27 tumor-necrosis factor-α, 
interleukin-1β,  and interleukin-2 can activate IDO to a lesser degree. Anti-
inflammatory cytokines (interleukin-4, interleukin-10, and transforming growth factor-
β) inhibit IDO induction by IFN-γ. 28 Thus, the balance between pro- and anti-
inflammatory cytokines is of importance to IDO-activity. 27 
Enzymatic Cofactors of the Kynurenine Pathway 
Pyridoxal 5’-phosphate 
The active form of vitamin B6, pyridoxal 5’-phosphate (PLP), is an enzymatic cofactor 
for transferring biological amines in multiple metabolic pathways. 29 Including KATs 






Riboflavin (vitamin B2) is a water-soluble vitamin present in milk, meat, fish, fruit, 
and vegetables, and its biologically active forms are involved in redox reactions. The 
activity of the oxidoreductase enzyme KMO can be decreased in riboflavin deficiency, 
as suggested by a ten-fold decrease in HK and a two-fold increase in KA in riboflavin-
deficient baboons. 31  
IMMUNOMODULATION BY KYNURENINE METABOLITES 
Experimental evidence suggests that the kynurenine pathway is not only induced by 
cytokines but has immunomodulatory and immunosuppressive actions. 32,33 IDO 
contributes to immune regulation by three main mechanisms. First, by acting as a 
signaling molecule influencing nutrient-sensing systems. Second, by depleting Trp, 
which activates amino-acid-sensing signal transduction pathways. Third, by producing 
Kyn, which acts as a natural ligand for the aryl hydrocarbon receptor (AhR), a 
transcription factor that inhibits immune responses. 2 By way of downstream signaling 
pathways, this suppresses CD8+ and CD4+ T-cells and stimulates regulatory T-cells 
(Tregs), promoting resolution of inflammation. 9 IDO deficient mice do not develop 
spontaneous autoimmune diseases. However, IDO inhibition reduces acquired 
tolerance to new antigens. 34 For example, pharmacological inhibition of IDO results 







KYNURENINE METABOLISM IN THE BRAIN  
The enzymes of the kynurenine pathway are expressed in the brain, with some 
variation between brain regions. 10 In the brain, IDO- and TDO-expression levels are 
relatively low. 36 Approximately 60% of brain kynurenine metabolism stems from 
circulating Kyn 37 which readily crosses the blood-brain barrier (BBB) and enters glial 
cells. 38 
The Blood-Brain Barrier 
The BBB restricts the influx of most compounds from the blood to the brain, 
generating an optimal internal milieu for neurotransmission. 39 Trp, Kyn, and HK cross 
the BBB by way of the large amino acid transporter. Conversely, KA and QA do not 
cross the BBB due to their polarity and lack of transporters. 40 Experimentally, 
extracellular KA and QA can be detected after intracerebral injections of Kyn and 
HAA, respectively. 41,42 KA and QA are cleared from the brain interstitial fluid by 
cellular uptake. 9,43 
Cellular Compartmentalization 
The enzymes of the kynurenine pathway are differentially expressed in cells of the 
brain. Astrocytes express KAT enzymes, but not KMO, and account for the 
biosynthesis of KA. 44 In contrast, microglia have a much lower expression of     
KATs, 45 but express KMO and generate HK, further converted to downstream 
kynurenines such as QA. Please see Figure 2 on the next page for a summary. After 
synthesis, both KA and QA are released into the extracellular space to affect their 
neuronal targets. 10 HK and PIC are synthesized in neurons. 46 In addition, 







Figure 2. Kynurenines and the blood-brain barrier. Tryptophan (Trp), kynurenine (Kyn), and 3-
hydroxykynurenine (HK) cross the blood-brain barrier (BBB), where kynurenic acid (KA) is mainly 
synthesized in astrocytes and quinolinic acid (QA) in microglial cells. Kyn is considered the primary 
precursor of kynurenines in the brain. After synthesis, QA is released into the extracellular space to 
affect the N-methyl-D-aspartate receptor (NMDAR) as an agonist, whilst KA acts as an antagonist on 
the NMDAR, and at the α-7 nicotinic acetylcholine receptor (α7nAChR). Adapted from Schwarcz et 
al10.  
Neuroactivity 
Some kynurenines display neuroactive properties. KA is an antagonist of the the N-
methyl-D-aspartate receptor (NMDAR), whilst QA is an NMDAR agonist. 48 
Additional receptors where antagonist activity has been reported for KA include α-7 
nicotinic acetylcholine receptor (α7nAChR), the kainate receptor, and the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptor. However, KA has the highest 
affinity for the glycine co-agonist site of the NMDAR. 9 Increased concentrations of 
QA may disrupt glutamatergic transmission in NMDA-expressing neurons, induce 




Experimental studies in rats suggest that KA is neuroprotective in brain ischemia 
and seizures by reducing excitotoxicity. 11 In contrast, intraventricular injection of QA 
produces convulsions in mice. 50 Further, QA injection into the prefrontal cortex of 
mice leads to cognitive and behavioral impairment and reduces hippocampal 
neuroplasticity. 51 
THE KYNURENINES IN GERIATRIC MEDICINE  
Clinical and experimental studies, mostly focused on Trp, Kyn, and KA, have 
identified associations between the kynurenine pathway and cognitive 
function, neurodegenerative disorders, and aging. These are major aspects of geriatric 
medicine. Notably, psychosis and mood disorders are prevalent in elderly patients, 
often secondary to neurological disease, and are in the context of brain disease referred 
to as neuropsychiatric symptoms. A number of high-quality studies on younger 
individuals have identified altered kynurenine pathway metabolite levels in blood, 
cerebrospinal fluid (CSF) and post-mortem brain samples from patients 
with schizophrenia and bipolar disorder with psychotic symptoms. 52 This highlights 
the need to investigate whether the kynurenines are associated with the development of 
neuropsychiatric symptoms.  
Cognitive Function 
Results from experimental studies investigating acute inflammation suggest that the 
kynurenine pathway may be a mediator of inflammation-related cognitive impairment. 
In rats, IDO-inhibition prevented sepsis-induced cognitive impairment after cecal 
ligation and perforation. 3 In line with this, IDO knockout prevented cognitive 
impairment in mice following lipopolysaccharide injection. 5  
Two cross-sectional studies have investigated the potential association between 
cognitive test performance and concentrations of metabolites of the kynurenine 
pathway in blood in patients without neurocognitive disorders (see Table 1 on the next 
page). However, both studies included small clinical populations with either severe 




levels of the kynurenines. Due to the neuroactivity of the kynurenines, experimental 
links to cognitive function, and immunomodulatory actions, there is a need to 
investigate the relationship between kynurenine metabolites and cognition in cohorts 
more representative of the general population. Notably, all metabolites are regulated 
around physiological concentrations, and thus non-linear associations could be present. 
However, the studies to date have focused on linear relationships.  
 
Psychiatric Disease and Behavioral Impairment 
The kynurenine pathway has been linked to major psychiatric disorders in patients 
without organic brain disease. 12 Post-mortem and CSF studies of schizophrenia show 
elevated concentrations of KA55 with similar findings in bipolar disorder. 52 Higher 
Kyn concentrations have also been linked to schizophrenia. 52 Higher KTR and lower 
KA plasma concentrations are also associated with depression. 56 In addition, patients 
who attempted suicide display higher QA and lower KA in plasma and CSF. 57 Mice 
with reduced NMDAR expression display severe behavioral abnormalities reminiscent 
of schizophrenia and autism. 58 In contrast, chronic excitotoxicity is linked to 
neurodegenerative disorders. 59 Despite these clinical and experimental findings, 
Table 1. Cross-sectional Studies on Kynurenines and Cognitive Function 





Population Fluid Measures Main findings 
Forrest et 






Serum KA, Kyn, 
KTR, 
neopterin 
Higher concentrations of 
KA, Kyn, KTR, and 
neopterin were 
associated with lower 
cognitive performance. 
Karu et al 
(2016) 54 
27 Stage IV renal 
failure 
Serum KA, Kyn, 
QA, XA, 
neopterin 
Higher concentrations of 
KA were associated with 
lower cognitive function. 
Abbreviations: KA, kynurenic acid; Kyn, kynurenine; KTR, kynurenine to tryptophan ratio; 




investigations into a potential role of the kynurenines in relation to the 
pathophysiology of neuropsychiatric symptoms observed in patients with organic brain 
disease are yet to be undertaken. 
Neurodegenerative Disease Leading to Dementia 
Several cross-sectional studies have investigated possible differences in circulating 
Trp and other kynurenines in patients with dementia compared to controls, focusing on 
Alzheimer’s disease (AD), the most common cause of dementia. These studies are 
summarized in Table 2 on the next page and have generally found lower Trp 
concentrations in AD patients compared to controls. However, the findings regarding 
concentrations of downstream kynurenines have been inconsistent. Plasma HAA, XA, 
and QA were lower in histopathologically confirmed AD. 60 However, Gulaj et al61 
found lower plasma KA and higher QA in patients with AD. KA concentrations in 
CSF were not significantly altered in patients with dementia with Lewy bodies (DLB) 
compared to controls. 62  
The kynurenine pathway is linked to both underlying inflammation, 
immunomodulation, and potential activity at the NMDAR, all of which are 
hypothesized to play a role in cognitive deterioration in dementia. 63 Several 
experimental studies have investigated the possible relationship between the 
kynurenine pathway and dementia. For example, IDO inhibition in AD knockin mice 
was related to less neurodegeneration and improved cognitive performance. 4 Previous 
clinical studies have identified that higher concentrations of QA are associated with 
lower cognitive function in elderly patients with AD. 60,61 Despite these clinical and 
experimental studies, there have been no investigations into whether kynurenine 
metabolites can predict longitudinal cognitive outcomes in patients with dementia.  
Neuropsychiatric symptoms are highly prevalent in dementia and have an adverse 
impact on patients’ quality of life and cognitive prognosis. 64 Notably, patients often 
have a range of neuropsychiatric symptoms such as psychotic symptoms, aggression, 
disinhibition, depression, anxiety, and aberrant motor behavior. 65 However, the 




symptoms whereas others do not is unclear. Studies on patients with bipolar disorder 
and schizophrenia have found higher KA concentrations, suggesting that the 
kynurenine pathway may be related to psychiatric disease with psychotic symptoms. 52 
Thus, investigations into the potential role of the kynurenine pathway in both cognitive 
prognosis and neuropsychiatric symptoms in patients with dementia are warranted. 
 
Table 2. Cross-sectional Studies on Kynurenines Comparing Patients with 





Population Fluid/Tissue Measures Main findings 










KA concentrations were 
lower in AD patients 
compared to Ctrls. 
Baran et al  
(1999) 67 




Brain tissue Kyn, KA, 
HK, PLP 
KA was lower in the 
caudate and putamen of 
AD patients compared to 
Ctrls. 





vs. Ctrls  
Serum Trp, Kyn, 
KTR 
Trp was lower, and Kyn 
and KTR were higher in 
AD patients compared to 
Ctrls. 
Hartai et al 
(2007) 69 
28 AD,  
13 Ctrls 




Kyn, KA KA concentrations were 
lower in AD patients 
compared to Ctrls. 
Gulaj et al 
(2010) 61 




Plasma Trp, Kyn, 
HK, KA, 
AA, QA 
Trp and KA were lower, 
and QA higher in AD 
patients compared to 
Ctrls. 
Wennström 
et al    
(2014) 62 
19 AD,  
18 DLB, 
 20 Ctrls 




KA KA concentrations were 
not altered in either AD or 
DLB patients compared to 
Ctrls. 
Giil et al 
(2017) 60 




Plasma Alla, PLP, 
neopterin 
Trp, HAA, XA, and QA 
concentrations were lower 
in AD patients compared 
to Ctrls. 
Jacobs et al 
(2019) 70 










Plasma Kyn and PIC 
inversely correlated with 
CSF p-tau and t-tau. 
Higher HK/Kyn ratio 
correlated with CSF p-tau 
and t-tau.  
Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; Ctrls, controls; DLB, dementia with 
Lewy bodies; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; KA, kynurenic acid; Kyn, 
kynurenine; KTR, kynurenine to tryptophan ratio; PIC, picolinic acid; PLP, pyridoxal 5’-phosphate; QA, 
quinolinic acid; Trp, tryptophan; XA, xanthurenic acid. 




Aging and Immunosenescence 
The chronic low-grade inflammation of aging, called “inflammaging” is likely to 
activate the kynurenine pathway with increasing age, 2 as aging is associated with 
increased interferon gamma (IFN-γ) and other pro-inflammatory cytokines. 71 Indeed, 
multiple cross-sectional studies suggest that this occurs. 72-80 C-reactive protein (CRP) 
is a commonly used biomarker to study inflammaging. 81 The kynurenines are 
immunoactive and could participate in the broader process of immunosenescence, 
characterized by a dysregulated immune system with vulnerability to infections, 
decreased self-tolerance, and reduced cancer surveillance. 9 The kynurenine pathway is 
also associated with adverse age-related outcomes, such as myocardial infarction, 82 
cancer, 83 frailty, 84 type II diabetes, 85 and obesity. 86 Due to this, and their capacity for 
immune regulation, the kynurenines have been proposed as biomarkers of 
immunosenescence. 2 
As proposed by Ingram et al87, a biomarker of aging should show 1) significant 
cross-sectional correlation with age and 2) significant longitudinal change with age 
consistent with the cross-sectional correlation. It should also display significant 
alterations with small age changes/increments.  
Table 3 on the next page summarizes previous studies that have investigated 
metabolism and the kynurenines in aging. All studies have used a cross-sectional 
design. The studies demonstrate cross-sectional correlation between chronological age 
and kynurenine pathway metabolites in serum/plasma and CSF, suggesting a 
relationship with human aging. However, this is not completely clarified as the 
absence of longitudinal studies makes it difficult to rule out a cohort effect. 88 
Moreover, most studies in Table 3 have focused on only a few select metabolites. 
Other studies have focused on select groups such as women or clinical populations, 
further limiting their external validity. 89,90 Taken together, longitudinal investigations 
into altered concentrations of kynurenine metabolites in human aging are warranted. 
Ideally, such investigations should include comprehensive measurements of 




persons. Further, due to the neuroactive properties of some kynurenine metabolites, 
CSF sampling would be of value.  
 
  
Table 3. Cross-sectional studies on Tryptophan and Kynurenines in Human Aging 
Author (year) Sample 
size 
Population Fluid Metabolites Main findings 
Frick et al (2004) 91 43 Healthy persons 34-
93 years old 
Serum Trp, Kyn, 
neopterin 
KTR and neopterin concentrations 
were positively correlated with older 
age. 
Kepplinger et al 
(2005) 80 




KA CSF-KA concentrations were 
positively correlated with age. 




CSF PIC PIC was positively correlated with 
age.  
Capuron et al 
(2011) 78 
284 Non-institutionalized 
persons >65 years 
old   
Serum Trp, Kyn, 
neopterin 
Trp was inversely associated with 
age, whilst Kyn, KTR, and neopterin 
were positively associated with age.  
Yu et al (2012) 77 2886 Persons without 
metabolic diseases 
Serum Trp Trp was inversely associated with 
age. 
Collino et al  




Serum Trp Trp was inversely associated with 
age.  
Theofylaktopoulou 
et al (2013) 75 
7052 Community-dwelling 
persons born during 
1925-27 and 1950-
51 
Plasma Trp, Kyn, 




Kyn, KA, AA, HK, KTR, and 
neopterin were higher in the older- 
versus middle-aged participants. 
De Bie et al   
(2015) 74 
49 Healthy women 20-
90 years old 
CSF Trp, Kyn, 
HK, HAA, 
KA, PIC, QA, 
neopterin 
Trp and HK were inversely correlated 
with age.  
KTR, PIC, and QA were positively 
correlated with age. 
Rist et al (2017) 73 301 Healthy adults 18-80 
years old 
Plasma Trp Trp concentrations were inversely 
associated with age. 
Ramos-Chávez et 
al (2018) 72 
77 Women over 50 
years old with normal 
cognitive function 
Serum Trp, Kyn, 
HK, KA. 
Trp was inversely associated with 
age, whilst the KA/Trp and HK/Trp 
ratios were positively associated with 
age. 
 
Abbreviations: AA, anthranilic acid; CSF, cerebrospinal fluid; CRP, C-reactive protein; HAA, 3-hydroxyanthranilic acid; HK, 3-
hydroxykynurenine; KA, kynurenic acid; KTR, kynurenine to tryptophan ratio; Kyn, kynurenine; PIC, picolinic acid; QA, 




THE RATIONALE FOR THE THESIS 
There is substantial experimental evidence linking the kynurenine pathway to aging, 
cognitive function, and dementia. However, there are gaps in the current knowledge. 
First, there have been no large community-based studies on relations between 
kynurenines and cognitive function. Second, there have been no longitudinal studies 
investigating whether the kynurenines predict cognitive and neuropsychiatric 
prognosis in dementia. Third and finally, due to the hitherto cross-sectional nature of 
the aging studies on kynurenines among selected populations with limited metabolite 
measurements, it is not clear whether and how aging may impact the kynurenine 
pathway. 72,73,75-78,91-93 
AIMS OF THE STUDIES 
1. To investigate cross-sectional associations between the kynurenines and 
cognitive function in community-dwelling older adults. 
2. To assess longitudinal associations between kynurenines, and cognitive 
prognosis in patients with mild dementia. 
3. To determine whether these associations (aims 1 and 2) were linear or non-
linear. 
4. To assess longitudinal associations between kynurenines, and neuropsychiatric 
symptoms in patients with mild dementia. 
5. To assess the relationship between the kynurenine pathway and human aging 
using several cohorts, including longitudinal studies with repeated metabolite 
measurements in the blood. 
6. To assess whether the kynurenine pathway is altered in the cerebrospinal fluid 
with aging and whether this is different from serum.  
7. To assess associations between kynurenines, frailty, and all-cause mortality. 






PARTICIPANTS IN THE STUDY AND CASE DEFINITIONS 
Study I 
The Hordaland Health Study (HUSK) is a community-based health survey conducted 
during 1992/93 and 1997/99 (https://husk-en.w.uib.no/). The principal aim of HUSK 
was to investigate lifestyle epidemiology and chronic diseases such as cancer, 
cardiovascular disease, osteoporosis, anxiety, depression, obesity, and diabetes. HUSK 
is an interdisciplinary collaborative study, which includes subprojects targeting 
psychosocial health, occupational medicine, musculoskeletal diseases, and cognitive 
function. Significantly, most participants donated blood samples to a biobank, 
including plasma and whole blood in 1997/99. The study focused on persons born 
during 1925-27 and 1950-52, of which we have included solely the oldest group where 
a large subgroup underwent cognitive testing. 94  
In 1997/99, 4338 community-dwelling older adults born in 1925-27, residing in 
Hordaland County, who had participated in 1992/93, were invited by mail to 
participate in a follow-up study. In all, 3328 older adults (76.7%) agreed to participate. 
The invitational letter included a self-administered questionnaire on, among other 
questions, education, smoking habits, use of medications, physical exercise, alcohol 
consumption, and history of angina pectoris, myocardial infarction, stroke, phlebitis, 
thrombosis, diabetes, and hypertension. Additionally, the participants answered the 
Hospital Anxiety and Depression Scale (HADS), designed to assess symptoms of 
anxiety and depression. Further, a comprehensive self-administered food-frequency 
questionnaire to assess habitual food intake was included. Study staff collected blood 
samples at the clinical examination, and recorded height, weight, waist and hip 





For the cognitive sub-study, 2841 individuals born in 1925-27 were invited to 
participate. The selection of these participants was based on their residence as the 
time-consuming nature of the cognitive test battery would be challenging for 
participants undertaking longer journeys to the study center. The included participants 
resided in the city of Bergen and three immediate surrounding municipalities. 
Participants were invited by letter and 2197 participants (77.3%) agreed to participate 
in the cognitive sub-study. Trained nurses at the study center administered a 
standardized cognitive test battery. Altogether, 2174 participants who underwent 
cognitive testing also had available blood samples and are included in our study.  
Study II 
The Dementia Study of Western Norway (DemVest) is a longitudinal cohort study of 
patients with mild dementia from multiple centers in Western Norway. 96 The principal 
aim of the study was to characterize biomarkers and disease progression in mild 
dementia focusing on Alzheimer’s disease (AD) and, in particular, DLB. Our study 
included 155 patients recruited from specialist clinics of neurology and old age 
psychiatry in Hordaland and Rogaland County who had available blood samples for 
metabolite measurements. These participants were recruited from 2005 to 2007. 
Dementia was defined according to the Diagnostic and Statistical Manual of Mental 
disorders, version four (DSM-IV). Patients were diagnosed with mild dementia using 
the following criteria: a Mini-Mental State Examination (MMSE) test score equal to or 
above 20 or a Clinical Dementia Rating (CDR) no higher than one. Patients with 
dementia due to Parkinson’s disease were also included. As DLB and Parkinson’s 
disease dementia have similar pathophysiology, they were classified together as Lewy 
body dementia (LBD). 96  
The study applied the National Institute of Neurological and Communicative 
Disorders and Stroke and Alzheimer’s disease and Related Disorders Association 
(NINCDS-ADRDA) criteria to diagnose AD, 97  and the revised consensus criteria for 
DLB (2005). 98 Consensus meetings regarding the diagnosis were held at baseline and 




consented to an autopsy, the diagnosis was revised following the neuropathological 
examination, as described previously. 99 A physician interviewed the patient alongside 
a caregiver, reviewed electronic health records, and performed a clinical and 
neurological examination.  
At baseline, cognitive function and dementia severity were assessed using the 
MMSE, CDR, and a standardized neuropsychological test battery, which have been 
described previously. 96 The MMSE and the Neuropsychiatric Inventory (NPI) were 
assessed at baseline and annually until death or dropout. However, most patients 
reached a zero score on the MMSE after five years of follow-up. Information 
regarding neuropsychiatric symptoms becomes challenging to evaluate in end-stage 
dementia. Thus, we censored the data after the fifth annual examination to avoid floor 
effects. 96 
Study III 
To investigate changes in kynurenines with human aging, we included data from four 
independent cohorts: two with repeated plasma measurements of kynurenines, the 
HUSK cohort of community-dwelling persons, and a cohort of CSF donors with 
repeated CSF measures in a subgroup.  
Melbourne Collaborative Cohort Study  
The Melbourne Collaborative Cohort Study (MCCS) was started in the 1990s to 
prospectively investigate the impact of diet and lifestyle on the development of cancer 
and other non-communicable diseases. 100 Study participants were primarily identified 
using electoral enrollment (compulsory) and phone directories. Advertisements and 
community announcements were used to recruit non-citizens. 100 The participants 
received an invitational letter and were sampled from 1990 to 1994 using the 
following criteria: Australian born residents and Greek-born or Italian-born migrants 
aged 40-69 years old at recruitment. Migrants were overrepresented to increase genetic 
variation and extend the number of lifestyle exposures. At the start of the study, 
participants filled out questionnaires concerning lifestyle (alcohol consumption, diet, 




Altogether, 67% of the participants provided fasting blood samples, while 33% 
donated non-fasting blood samples. Most of the measurements and blood samples 
gathered at baseline were repeated for 26 824 participants during the first follow-up 
conducted from 2003 to 2007. A subset of 970 participants with repeated 
measurements of the kynurenines in plasma (baseline, and follow-up after a median of 
eleven years) were included. All study participants provided informed consent 
according to the Declaration of Helsinki. 100 Vital status was ascertained through 
linkage of the cohort to the Victorian Registry of Births Deaths and Marriages through 
the Victorian Cancer Registry and the National Death Index through the Australian 
Institute of Health and Welfare. 
Hordaland Health Study 
Community-dwelling older adults (n = 3136) aged 71-74 years old with non-fasting 
plasma samples and mortality data from HUSK were included. 94 In addition, a subset 
of 1691 participants who underwent cognitive testing with available non-fasting 
plasma samples were included for the construction of a frailty index (Please see 
METHODS; Study I p. 33 for the full description of the cohort). 
Western Norway B Vitamin Intervention Trial 
The Western Norway B Vitamin Intervention Trial (WENBIT) is a prospective, 
double-blind, placebo-controlled secondary prevention study investigating the clinical 
effects of B vitamin intervention. 101 The study included patients who underwent 
coronary angiography for suspected coronary artery disease. The 3090 study 
participants were recruited at Haukeland University Hospital, Norway (January 2000 – 
April 2004), and Stavanger University Hospital, Norway (September 2000 – April 
2004). 101 All participants underwent a routine clinical interview and examination 
before coronary angiography at the study baseline. Exclusion criteria were 
unavailability for follow-up, participation in other trials, known alcohol abuse, cancer, 
or severe mental illness. The participants were randomized to one of four arms: 1) 
vitamin B6, 2) vitamin B12/folate, 3) B12/folate/B6, and 4) placebo supplementations. 




samples were included in the analyses. Follow-up visits were scheduled at one month, 
one year, and a final study visit. As the aim of the current study was to investigate age-
related changes in kynurenines, the one-month follow-up was excluded. The mean 
time to the final study visit was three years after baseline for the placebo group. Thus, 
repeated measurements of Trp, the kynurenines, and CRP were available from 
baseline, one-year, and three-year follow-up. Each visit involved an interview, a 
clinical examination, and blood sampling. Participants unable to attend visits 
underwent a telephone interview or answered a questionnaire sent by mail. 101   
Elective Surgery Cohort 
The elective surgery cohort on CSF from Cognitively Normal Persons (COGNORM) 
is a collaborative study between Oslo University Hospital and Diakonhjemmet 
Hospital, Oslo, aiming to assess CSF and magnetic resonance imaging (MRI) 
biomarkers in cognitively healthy persons. 102 The participants were scheduled for 
elective surgery (gynecological, orthopedic, or urological) and CSF was sampled at the 
onset of spinal anesthesia. 102 It included 172 participants (≥65 years) during 2012 and 
2013. 103 The term “cognitively healthy” was defined as scoring >27 points on the 
MMSE and not being referred to a memory clinic. Patients were also tested using a 
neuropsychological test battery. Based on this, they were still defined as cognitively 
healthy if the MMSE was ≤ 27 points and just one other test score was more than 1.5 
standard deviations (SD) outside the age, education, and sex-based normative value. 
Exclusion criteria were a history of stroke with sequela and other neurodegenerative 
diseases affecting cognitive function. In the current study we included 109 patients 
who had available CSF and serum samples at baseline, and 33 patients volunteered to 






The HUSK study was approved by The Regional Committee for Medical and Health 
Research Ethics (REK approval no.: 2016/2208). Participants provided written consent 
to participate in the study. 
Study II 
The DemVest study was approved by The Regional Committee for Medical and 
Health Research Ethics (REK approval no.: 2010/33). Participants provided written 
consent after a detailed explanation of the study procedures were explained in the 
presence of a caregiver.  
Study III 
HUSK (REK approval no.: 2016/2208), WENBIT (REK approval no.: 2013/2022), 
and COGNORM (REK approval no.: 2011/2052) were approved by The Regional 
Committee for Medical and Health Research Ethics in Norway. The MCCS was 




PSYCHOMETRICS AND CLINICAL SCORING SYSTEMS 
Study I: Cognitive Performance and Depressive Symptoms 
Ceiling effects were identified in both a brief version of the MMSE and Block-Design 
(Study I: Supplementary Figure 1). This implies that cognitive function was not 
accurately measured in participants who reached the ceiling effects. Further, the Trail 
Making Test A displayed a log-normal distribution with a bimodal trend. These three 
cognitive tests were therefore considered unsuitable as measurements of variation in 
normal cognitive function. 
Three cognitive tests were normally distributed (Study I: Supplementary      
Figure 2), indicating an appropriate difficulty level with a centralized mean, and were 
selected to describe cognitive function in community-dwelling older adults: The 
Controlled Word Association Test (COWAT), Digit Symbol Test (DST), and 
Kendrick Object Learning Test (KOLT). The COWAT is considered a measure of 
language, memory, and executive function. The test encourages participants to write as 
many words as possible, beginning with a given letter, in 60 seconds. 104 The DST is 
considered to measure executive function. To perform the DST, the participant is 
given a single sheet of paper and an assignment to match symbols to numbers 
according to a key located on the top of the page. 105 The participant copies the symbol 
into spaces below a row of numbers. The number of correct symbols within the 
allowed time, usually 90 to 120 seconds, constitutes the score. 106 Lastly, KOLT 
measures immediate recall and requires participants to observe picture charts before 
telling the examiner what they observed. 107 KOLT is considered valid and reliable in a 
broad range of older persons: community-dwelling, depressed patients, patients with 
dementia, and institutionalized elderly. 108 
Depression is independently associated both with cognitive function and with 
kynurenine concentrations, and may therefore act as a confounder in the relation 
between the two.109 We assessed depressive symptoms using the HADS, a screening 
tool for mood disorders. 110 HADS includes fourteen statements on emotions and 




scoring system ranges from zero to three, indicating probable absence, possible 
presence, and the probable presence of an anxiety or mood disorder. The maximum 
score is 42, with a higher score indicating probable/possible mood disorder. 110 We 
defined a score of ≥ 8 as indicative of mild depressive symptoms, in accordance with 
Stern et al110. The sensitivity and specificity for HADS are both approximately 0.80. It 
performs reasonably well in assessing symptom severity and caseness for depression 
and anxiety disorders in somatic, psychiatric, and primary care patients and in the 
general population. 111 
Study II: Longitudinal Evaluation of Cognitive Performance 
The MMSE has a maximum score of 30, a minimum score of zero, and consists of 
multiple questions grouped into seven categories. These include orientation to time, 
orientation to place, registration of three words, attention and calculation, recall of 
three words, language, and visual construction. These are summed to give a global 
cognitive score. 112 The MMSE's simplicity is an advantage in longitudinal studies of 
dementia, as patients are typically unable to perform more complex 
neuropsychological tests as the disease progresses. The annual decline in MMSE score 
in patients with dementia is around three points, and a two to four points reduction is 
considered a reliable change. 113 Antemortem cognitive impairment measured by the 
MMSE is consistently associated with amyloid-beta (Aβ) plaques, neurofibrillary 
tangles and a decreased number of synapses. 114 The MMSE demonstrates satisfactory 
reliability and construct validity and displays high levels of sensitivity for moderate-
to-severe cognitive impairment. However, the MMSE is less sensitive in detecting 
patients with mild cognitive impairment. 112 
Study II: Longitudinal Assessment of Neuropsychiatric Symptoms 
The NPI evaluates twelve neuropsychiatric symptoms that may occur in dementia: 
delusions, hallucinations, agitation, anxiety, dysphoria, apathy, euphoria, disinhibition, 
irritability, aberrant motor behavior, disturbances of sleep, and appetite disturbances. 




symptoms and asked if they are present. If present, the caregiver is asked to rate the 
severity and frequency of each neuropsychiatric symptom using a standardized 
questionnaire. A combined score for each symptom is calculated by multiplying the 
frequency by severity. The total score is calculated by adding all the domain scores 
together. 115 The NPI is considered valid and reliable with regards to concurrent 
validity, intra- and interrater reliability, test-retest reliability, and internal   
consistency. 116 
Study III: Frailty Index  
To investigate the potential relationship between frailty and the kynurenines, we 
followed the stepwise procedure to construct a frailty index described by Rockwood et 
al117. Thirty-eight health conditions/deficits (binary, ordinal, and continuous variables) 
were included from 2152 HUSK participants who underwent cognitive testing. The 
number of deficits was divided by the total number of possible deficits, resulting in a 
frailty index score from zero to one. However, there were missing data for several 
participants. We excluded participants with missing information on six or more 
conditions and adjusted the denominator to available health deficits. Thus, the frailty 
analyses included measurements from 1691 participants in HUSK with information on 
more than 32 health deficits for each participant. Of these, 327 participants had all 
available data (i.e. no missing data) for the potential 38 deficits registered, 633 had one 
deficit missing, 329 had two deficits missing, and 190 had three or more missing 
deficits. The frailty index is well validated. 118 Several studies have found that this 
frailty index has a higher predictive ability for adverse outcomes than other frailty 
scores, both in hospital and community settings. 119 The total frailty index score, rather 
than individual health deficits, is typically the most predictive of adverse outcomes. 
An upper limit of deficit accumulation measured by the frailty index is estimated to be 





BLOOD SAMPLES AND METABOLIC BIOMARKERS 
Measurements of Trp, the kynurenines, and inflammatory markers were performed in 
five cohorts (see Table 4). Trp, the kynurenines, PLP, and neopterin were measured 
using liquid chromatography-tandem mass spectrometry. 120 CRP was measured using 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. 121 The 
samples were stored at -80◦C in all five cohorts. KTR was defined as Kyn (µM)/Trp 
(µM) * 100. The limit of detection for the kynurenines and neopterin ranged from 0.5 
nmol/L to 7 nmol/L, while the limit of detection for Trp was 0.4 µmol/L. Within-day 
and between-day coefficients of variation were 5.7-16.9% and 3.0–9.5 %, respectively. 
For CRP, the limit of detection was 0.2 µg/L, and within- and between-day 
coefficients of variation were 5.5–8.4 % and 7.0–11.7 %, respectively. The 
biochemical analyses of biomarkers included in this thesis were performed at the 
Bevital AS laboratory (Bergen, Norway, http://bevital.no). 
Table 4. Biomarker Measurements in Five Cohorts.   
Cohort (Study) Population Fasting status Fluid 
HUSK (I, III) Community-dwelling Non-fasting Plasma 
DemVest (II) Mild dementia Fasting Serum 
MCCSa (III) Community-dwelling Fasting / non-fasting Plasma 
WENBIT (III) Stable angina pectoris Non-fasting Plasma 
COGNORMb (III) Elective surgery Fasting/ non-fasting Serum / CSF 
Abbreviations: COGNORM, Elective Surgery Cohort; CSF, cerebrospinal fluid; DemVest, Dementia Study of Western 
Norway; HUSK, Hordaland Health Study; MCCS, Melbourne Collaborative Cohort Study; WENBIT, Western Norway B 
Vitamin Intervention Trial. 
a In the MCCS, 67% of the participants provided fasting blood samples at baseline, with 90% fasting samples at follow-up.  
b In COGNORM, 109 participants donated CSF samples per-operatively during elective surgery, and of these, 33 volunteered 









In all studies, metabolite concentrations are reported as median concentrations, and the 
variance is reported using the interquartile range, as the metabolites did not follow a 
normal distribution. Univariate analyses were conducted using the Mann-Whitney U-
test and Spearman’s Rho (Rs) correlation coefficients. Multivariable analyses were 
conducted following both statistical transformations to obtain normality and scaling, 
the latter by standardization (i.e. z-scores where all variables have a mean of zero and 
a SD of one). The mean following log-transformation corresponds to the geometric 
mean. 
Hypothesis Testing and Multiple Comparisons 
Adjustment for multiple comparisons aims to maintain the nominal alpha, thus 
reducing false-positive findings (type I errors), which increases as a function of the 
number of hypotheses tested. There are several methods that can achieve this aim. In 
study I, we applied the Bonferroni correction. This method's main disadvantage is that 
it can lead to a higher rate of type II errors. 122 However, due to the relatively large 
sample size in study I, occurrence of type II errors was not a significant concern. In 
study II, we used a method based on the false-discovery rate 123 adapted to correlated 
predictors, as is the case with the kynurenine metabolites. In study II, in contrast to 
study I, the sample size was relatively small. We thus wanted to avoid the inflation of 
the type II error rate typically associated with using the Bonferroni correction. In 
study III, generally, we could assess the same hypotheses (that kynurenine 
metabolites are associated with aging) across independent populations. As the 
probability of finding two significant p-values in independent studies is much lower, 







To find optimal statistical transformations of metabolite concentrations to a normal 
distribution, we applied Tukey’s ladder of powers.124  Cognitive tests are frequently 
correlated with each other, as was the case for COWAT, DST, and KOLT. In order to 
identify whether the kynurenines were associated with one of these tests, adjusted for 
the between-test associations, we applied multi-outcome regression, namely Zellner’s 
seemingly unrelated regression (SUR). 125 Linear regression assumes that the outcomes 
are independent. In the SUR model, the Breusch-Pagan test was highly significant, 
confirming dependent outcomes and the appropriateness of a SUR model. A two-step 
estimation procedure was applied. We could not formulate a hypothesis specifying 
which metabolite is associated with which cognitive test. Accordingly, we tested the 
joint significance of the association between each metabolite and the three cognitive 
outcomes. These were executive function (DST), language (COWAT), and memory 
(KOLT). Specifically, the joint significance was tested using the Wald test on a 
composite linear hypothesis of association between the metabolite and the three 
cognitive tests. The joint significance (α = 0.05) threshold was then adjusted for the 
number of hypotheses tested, according to the Bonferroni method. 122 We first 
estimated an unadjusted model, followed by adjustment for the a priori identified 
confounders: age, sex, body mass index, education (in years), estimated glomerular 
filtration rate (GFR), current smoking, diabetes, previous myocardial infarction, prior 
stroke, and PLP. Further, we evaluated whether metabolites were associated with 
depressive symptoms on HADS (score ≥ 8), 110 anti-depressant use 126, non-steroidal 
anti-inflammatory drugs use, 127 and CRP. 128 We included any significant association 
into the SUR model.   
Study II 
The metabolite concentrations were transformed to a normal distribution following 
Tukey’s ladder of powers.124 We used a joint model to estimate the association 
between, Trp and the kynurenines, and the dependent variables, MMSE score and the 




baseline and annually for five years. There were occasional delays, and some patients 
were followed for six years so the data were unbalanced. MMSE test scores were 
transformed using the square root of errors transformation; √(30-MMSE). Following 
this transformation, higher values indicated poorer cognitive performance. The MMSE 
reached a ceiling-effect. We therefore implemented right censoring using a linear 
mixed-effects Tobit model. This model included random intercepts and slopes.  
The NPI-total score was fitted using a negative binomial random-intercept model, 
selected as per the Bayesian information criterion. 129 Likely related to the 
considerable variation in neuropsychiatric symptoms over time, random slopes could 
not be fitted. The MMSE and NPI-total models were linked in a joint-model by 
allowing their respective random effects to be correlated, using a generalized structural 
equation model framework (Stata 15 package “gsem”). The metabolites were 
measured at baseline only. Due to strong correlations between metabolites, risking 
collinearity, each metabolite was entered as a predictor in separate joint models with 
MMSE and NPI as outcomes. Covariates included years in study (time), age, age*time 
interaction, sex, AD vs. LBD, AD vs. LBD*time interaction, current smoking, GFR, 
and PLP in the MMSE sub-model. Compared to study I, we included only the most 
important confounders as sample size limited the possibility for more complex models. 
The same covariates were used in the NPI-total sub-model, excluding the non-
significant age*time interaction. In brief, each metabolite in the joint-models predicted 
MMSE and NPI, adjusted for the association between these two outcomes, and 
covariates. The potential presence of non-linearity was evaluated using orthogonal 
polynomials of the transformed metabolite concentrations. Post-hoc, we re-estimated 
the above model stratified by diagnosis. We applied logistic mixed-effects models with 
random intercepts to estimate associations between metabolites and individual items of 
the NPI. The items were classified as present or not present, and covariates were 
included as described above for the sub-model with the NPI-total score as the 
outcome. Effect sizes are reported as fixed effects (FE), referred to as estimates in 




based false discovery rate due to dependency, and adjusted p-values are reported (Q-
values, or Q). This was done separately for post-hoc tests (R package: fdrtool).  
Study III 
Trp and the kynurenine metabolites were outcomes in random intercept models (as 
MCCS had two repeated measurements) or random coefficient models (WENBIT had 
three repeated measurements). We estimated a model with baseline age and time (in 
study) as the only predictors. Time was a category (0 for baseline, 1 for follow-up) in 
the MCCS, and change per year was calculated by dividing the effect sizes by 11 due 
to a median follow-up time of 11 years. In WENBIT, the exact time of follow-up 
occurred at a median of one and three years, and due to variations, time was entered as 
a continuous variable.  
These analyses provided partially standardized fixed effects on the log-scale 
where a one-year change in years in study or age gave a one SD change in the 
standardized log-transformed outcome. Further, we reported fully standardized fixed 
effects, calculated by multiplying the partially standardized coefficients by the SD of 
the predictors. The effect sizes have a similar interpretation as correlation coefficients.  
The survival analyses in MCCS and HUSK were performed using Cox regression, 
after determining that the models were in line with the assumption of proportional 
hazards. The analyses were adjusted for the covariates age, sex, and GFR. The 
baseline for survival analysis in the MCCS was after the last biomarker assessment at a 
median of 11 years, as endpoints were available only after this time-point. 
Investigation of associations between Trp, the kynurenines, and CRP and the frailty 
index (HUSK) were performed using a standardized linear regression model, adjusted 
for age and sex (as GFR was included in the frailty index). For the purpose of log-
transformation, the frailty index was multiplied by 100, and a constant of one was 
added prior to log-transformation and subsequent scaling to a z-score. 
The sample size in COGNORM prevented the assumption of a normal distribution 




and the kynurenine metabolites in serum and CSF using non-parametric Spearman’s 
Rho. Further, we explored if the correlation coefficients between age and the 
kynurenines in sera were equal to the correlation coefficients between age and the 
kynurenines in CSF, adjusted for the metabolites’ correlation between each other. 130 
The Wilcoxon signed-rank test was used to compare metabolite concentrations 







Characteristics of the Study Participants  
Community-dwelling older adults (n = 2174) (55% women) from HUSK, with 
cognitive test scores and available blood samples were included in the study. The 
mean (SD) scores for the cognitive tests were: COWAT, 15 (5.5); DST, 10 (4.2); and 
KOLT, 35 (8.1). Please see Study I: Results, p. 158, and Table 1, p. 159. 
The Kynurenine Pathway and Cognitive Performance 
Higher plasma concentrations of KTR and neopterin were associated with reduced 
cognitive performance in the domains of memory (KOLT) and language (COWAT) 
(Figure 3 on the next page. From Study I: Figure 2, p. 158). This association was not 
present for executive function (DST). Of the two identified predictors, KTR was most 
associated with cognitive performance (please see Study I: Table 2, p. 159). In 
addition to adjusting for the a priori identified covariates age, sex, body mass index, 
education, GFR, current smoking, diabetes, previous myocardial infarction and stroke, 
and PLP, we evaluated other potential confounders. The kynurenines were not 
associated with depression as defined by a HADS score on the depression subscale ≥ 
8, or the use of anti-depressants. The kynurenines were, however, associated with CRP 
levels and the use of NSAIDs (Study I: Table 3, p. 160). However, adjustment for 
CRP or NSAIDs use did not attenuate the associations between KTR, Kyn, neopterin 





Figure 3. Cognitive Tests and Markers of Immune Activation. Predicted results from Zellner’s 
seemingly unrelated regression, adjusted for age, sex, body mass index, educational level, estimated 
glomerular filtration rate, current smoking, diabetes, hypertension, previous myocardial infarction, prior 
stroke, and pyridoxal 5’ phosphate as covariates.  
Abbreviations: COWAT, Controlled Oral Word Association Test; KOLT, Kendrick Object Learning Test; 
KTR, kynurenine to tryptophan ratio.  







Characteristics of the Study Participants  
Patients with dementia (n = 155, 90 AD, 65 LBD, 56.1% women) were included from 
DemVest. At baseline, the patients had a mean MMSE score of 23.7, a mean education 
of 9.7 years, and 20% indicated current smoking (Study II: Table 1, p. 4).  
Non-Linear Kynurenine-MMSE Association in Mild Dementia 
Serum Kyn concentrations measured at the beginning of the study displayed a non-
linear association with the average MMSE score over the five annual follow-ups. 
Specifically, the first polynomial of Kyn (FE -0.023 (referred to as estimate in Study 
II), Q > 0.05) did not show an association with cognitive function, whereas the second 
polynomial of Kyn did (FE 0.10, Q = 0.046), showing a significant quadratic 
association (Figure 4 on the next page. From Study II: Figure 2, p. 6). Kyn was not 
associated with the rate of cognitive decline in patients suffering from mild dementia. 
None of the other kynurenine metabolites were associated with cognitive performance 
(Study II: Table 2, p. 5). There were no significant differences in this association 
when the analyses were stratified according to a diagnosis of AD or LBD (data not 
shown).  
Kynurenines and Neuropsychiatric Symptoms 
We first estimated the associations between kynurenines and the NPI-total score. 
Higher serum kynurenic acid to kynurenine ratio (KKR) was not associated with 
neuropsychiatric symptoms at baseline (FE -0.050, Q > 0.05). However, higher KKR 
was associated with an increase in the NPI total score per year (FE 0.063, Q = 0.045), 
see Figure 5 on the page following the next page (p. 52), from Study II: Figure 3, p. 6. 
KA and XA also displayed a trend of being associated with increasing 
neuropsychiatric symptoms over time but were not significant following adjustment 
for multiple comparisons. Post-hoc, we estimated the associations between individual 




over time and KA was associated with more hallucinations overall without affecting 
the longitudinal development of hallucinations (both Q < 0.05) (Study II: Figure 4, p. 
7).  There were no significant differences in these associations between LBD and AD 
(data not shown). 
 
 
Figure 4. Non-Linear Association Between MMSE Test Scores and Serum Kynurenine. 
Kynurenine concentrations around the geometric mean was not associated with MMSE, whereas high 
or low serum concentrations were associated with more MMSE-errors. The model was estimated as a 
joint model together with a model for the NPI-total score (see statistics). Of note, a constant of one 
was added to kynurenine prior to logarithmic transformation, shifting the log (mean) from 0.55 to 
1.02.   
Abbreviations: MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.  








Figure 5. The Kynurenic Acid to Kynurenine Ratio and Neuropsychiatric Symptoms. The graph 
shows how a change in one standard deviation of the transformed and standardized levels of KKR 
(the reciprocal of 1/√(KKR)) was associated with an increase in neuropsychiatric symptoms over time, 
using a negative binomial random-intercept model linked to the MMSE model (i.e., a joint model), 
adjusted for age, sex, current smoking, estimated glomerular filtration rate, and PLP in the model for 
NPI-total score.  
Abbreviations: KKR, kynurenic acid to kynurenine ratio; MMSE, Mini-Mental State Examination; NPI, 
neuropsychiatric inventory; PLP, pyridoxal 5’-phosphate. 







Characteristics of the Study Participants 
The characteristics of the study participants in the four independent cohorts are 
summarized below and in Study III: Table 1, p. 30.  
Melbourne Collaborative Cohort Study  
Community-dwelling participants (n = 970, 32% women) with a mean (SD) baseline 
age of 57.6 (7.9) years were included in the study. Plasma concentrations of Trp, the 
kynurenines, and CRP were measured at baseline and at follow-up after a median of 
eleven years. Mortality data were recorded until 16 years after the follow-up. 
 
Western Norway B Vitamin Intervention Trial 
Patients with stable angina pectoris (n = 604, 22.9% women) with a mean (SD) age of 
61.9 (9.7) years at baseline were included in this study. Trp, the kynurenines, and CRP 
were measured at baseline and at two follow-up visits after a median of one and three 
years.  
 
Hordaland Health Study 
Community-dwelling older adults aged 71-74 years old (n = 3161, 44.3 % women) 
who had donated blood samples were included in this study. Mortality data were 
recorded until 17 years after baseline. A subset of 2152 older adults underwent 
cognitive testing, of which 1691 participants had sufficient data to compute a frailty 
index.  
Elective Surgery Cohort 
Patients undergoing elective surgery (n = 109, 46% women) with a mean (SD) age of 
73.3 (6.8) years provided CSF and serum samples and were included in the analyses. 





Associations Between Kynurenines and Age  
The associations between age, time and metabolites were characterized by FE from a 
multilevel model where metabolites were outcomes with age and time as independent 
variables. The estimated FE represents a one SD change in log-transformed plasma 
biomarker concentrations per year of age or time in study.  
In MCCS, a study on community-dwelling persons, the strongest associations with 
age were for QA, KTR, and Kyn. The estimated associations with age were weaker for 
HK, CRP, KA, and AA. In contrast, Trp was inversely associated with age. Please see 
Figure 6 on the next page. From Study III: Figure 2, p. 25. 
In WENBIT, a study on patients with stable angina, KTR, QA, and Kyn displayed 
the strongest associations with age. There were weaker associations between age, HK, 
KA, and AA. Again, Trp was inversely associated with age. Please see Figure 7 on the 
page after the next page (p. 56). From Study III: Figure 3, p. 27. 
Changes in Kynurenine Concentrations Over Time 
Samples in MCCS were taken at baseline and again after a median of 11 years. Figure 
6 (on the next page) summarizes changes in the kynurenine metabolites with age, and 
over time in MCCS. We identified an increase in plasma KTR and QA over time, with 
smaller increases in Kyn, HK, KA, and HAA. Trp and anthranilic acid (AA) decreased 
over time.  
Samples in WENBIT were taken at a median of one and three years after baseline. 
Figure 7 (on the page after the next page (p. 56)) summarizes changes in the 
kynurenine metabolites with age, and over time in WENBIT. Here, plasma QA and 
KTR increased. However, QA was measured only at baseline and after one year. Kyn, 
HK, KA, AA, HAA, and XA increased to a lesser extent over time, whereas Trp 
decreased. By comparison, CRP showed minor associations with age and inconsistent 
changes over time in MCCS and WENBIT. Standardized fixed effects, which can be 
interpreted similarly to correlation coefficients, can be found in Study III: 





Figure 6. Metabolites of the Kynurenine Pathway Change with Age (upper panel), and Over 
Time (lower panel) in Community-Dwelling Persons (MCCS study). The mean age of MCCS 
participants were 57.6 years at baseline, with follow-up after 11 years. Log-transformed and 
standardized metabolites (with CRP as a reference) were entered as outcomes in linear mixed-effects 
models with baseline age and time as predictors. In the model, time was a categorical variable, and 
the effect sizes for time were divided by 11 to yield change per year. The fixed effects reflect a one 
standard deviation change in the standardized, log-transformed metabolite concentration per year of 
chronological age or per year in the study. Of note, the x-axes for the fixed effects on the upper and 
lower panels are on different scales. 
Abbreviations: AA, anthranilic acid; CRP, C-reactive protein; HAA, 3-hydroxyanthranilic acid; HK, 3-
hydroxykynurenine; KA, kynurenic acid; KTR, kynurenine to tryptophan ratio; Kyn, kynurenine; MCCS, 
Melbourne Collaborative Cohort Study; p, p-value; QA, quinolinic acid; Trp, tryptophan; XA, 
xanthurenic acid; 95% C.I., 95% confidence interval.  





Figure 7. Metabolites of the Kynurenine Pathway Change with Age (upper panel), and Over 
Time (lower panel) in Patients with Stable Angina Pectoris (WENBIT study). The mean age of the 
patients was 61.9 years at baseline, and they were followed up after a median of one and three years. 
Metabolites (and CRP as a reference) were log-transformed, standardized and entered as outcomes 
in linear mixed-effects models with age at the study baseline and time (years in study) as predictors. 
The fixed effects reflect a one standard deviation change in the standardized, log-transformed 
metabolite per year of chronological age or per year in study. Of note, the x-axes for the fixed effects 
on the upper and lower panels are on different scales.  
Abbreviations: AA, anthranilic acid; CRP, C-reactive protein; HAA, 3-hydroxyanthranilic acid; HK, 3-
hydroxykynurenine; KA, kynurenic acid; KTR, kynurenine to tryptophan ratio; Kyn, kynurenine; p, p-
value; QA, quinolinic acid; Trp, tryptophan; WENBIT, Western Norway B Vitamin Intervention Trial; 
XA, xanthurenic acid; 95% C.I., 95% confidence interval. 




Metabolite Concentrations in Persons Aged 71 to 74 Years in HUSK 
Plasma Trp was lower in persons aged 74 years old compared to those aged 71 years. 
In contrast, HK, KTR, QA, and CRP were higher, although CRP did not reach 
statistical significance. HK was also higher in persons aged 73 years compared to 
those aged 71 years. QA was also higher in persons aged 72 or 73 years compared to 
those aged 71 years (Study III: Table 2, p. 31).  
Aging and Kynurenine Pathway Metabolites in the Cerebrospinal Fluid 
In the 109 participants from COGNORM, statistical analyses were conducted using Rs 
to estimate correlation coefficients. The metabolites in serum correlated moderately 
(HK, KA, Trp) to strongly (QA, PIC, Kyn) with the corresponding CSF-metabolites. 
HK and PIC were not correlated with age in either serum or CSF. Trp was 
significantly, inversely correlated with age in the serum        (Rs -0.27) and positively 
but non-significantly in the CSF (Rs 0.14). Kyn correlated significantly with age in 
serum (0.24) but more so in the CSF (0.39). KA correlated non-significantly with age 
in serum (Rs 0.15) but significantly in the CSF (Rs 0.32), whereas AA was more 
correlated with age in serum (Rs 0.29) than in the CSF (Rs 0.23). Finally, QA was most 
strongly correlated to age in serum (Rs 0.37) and in the CSF (Rs 0.55). The correlation 
between metabolites and age was significantly stronger in the CSF than in serum for 
QA and Kyn (Table 5A on the next page). Compared to the first age-quartile, CSF-QA 
concentrations doubled in the fourth quartile (Table 5B on the next page). In the 
subgroup of 33 participants with a second lumbar puncture after four years, Kyn 
(median 51.4 nmol/L at baseline, 57.7 after four years, p < 0.001) and QA (median 
31.2 nmol/L at baseline, 42.6 after four years, p < 0.001) increased, whereas HK 
increased marginally (median 4.42 nmol/L at baseline, 4.91 after four years, p = 
0.038). There was no significant change in Trp, KA, AA, and PIC (Table 5C on the 






Table 5A. Serum and Cerebrospinal Fluid Correlations with Age for Tryptophan 
and Kynurenines in 109 Cognitively Healthy Persons Undergoing Elective Surgery 
   
  Correlations between 
metabolitesa 
 Correlations between 
metabolites and agea 
 Difference in  
serum vs. CSF age-correlationsb 
  Serum vs. CSF  Serum  CSF  Null-hypothesis of equivalence 
Trp  0.26*  -0.27*  0.14  .001* 
Kyn  0.68**  0.24*  0.39**  .039* 
HK  0.40**  0.17  0.17  .999 
KA  0.28*  0.15  0.32**  .136 
AA  0.36**  0.29*  0.23*  .574 
PIC  0.70**  -0.11  0.03  .067 
QA  0.78**  0.37**  0.55**  .001* 
         
Table 5B. Quinolinic acid concentrations in nmol/L according to age-quartiles 
  Serum  CSF  % in CSF vs. Serum 
  Median (IQR)  Median (IQR)  Median (IQR) 
64-68  373 (158)  29.4 (10.1)  7.95 (2.62) 
69-71  398 (267)  33.0 (20.3)  8.74 (2.64) 
72-77  429 (135)  42.7 (16.1)  8.75 (4.28) 
78-91  647 (723)  65.9 (65.1)  10.6 (3.52) 
       
Table 5C. Change in cerebrospinal fluid kynurenines over four years (n = 33)c 
         
  Baseline  Four-year follow-up   
  Median (IQR)  Median (IQR)  pd 
Trp  2.64 (0.7)  2.64 (0.6)  .774 
Kyn  51.4 (14.2)  57.7 (29.9)  <.001** 
HK  4.42 (2.27)  4.91 (2.45)  .038* 
KA  2.47 (1.33)  2.25 (1.13)  .816 
AA  9.48 (7.18)  10.9 (2.88)  .788 
PIC  19.2  (8.2)  18.9 (7.4)  .469 
QA  31.2 (20.3)  42.6 (24.7)  <.001** 
Note: CSF concentrations of HAA and XA were below the limit of detection and thus omitted from this analysis.  
Abbreviations: AA, anthranilic acid; CSF, cerebrospinal fluid; HK, 3-hydroxykynurenine; IQR, interquartile range; KA, 
kynurenic acid; Kyn, kynurenine; p, p-value; PIC, picolinic acid; QA, quinolinic acid; Trp, tryptophan.  
a Spearman’s Rho correlation coefficients. 
b Equivalence of correlation coefficients in serum and CSF samples in paired samples, p < 0.05 indicates a significant 
difference. 130 
c Trp, HK, KA, AA, and PIC in μmol/L, Kyn and QA in nmol/L. 
d Wilcoxon signed rank test for paired samples. 
* p <0.05; ** p < 0.001. 





Kynurenines Concentrations and Frailty in HUSK  
Using the frailty index score as the outcome, plasma CRP showed the strongest 
association with frailty. Significant associations with frailty were identified for several 
kynurenines adjusted for age, sex, and CRP: QA (β 0.11, p < 0.001), Kyn (β 0.10, p < 
0.001), KTR (β 0.10, p < 0.001), HAA (β 0.08, p<0.001), KA (β 0.08, p = 0.002), and 
HK (β 0.07, p = 0.007). However, following adjustment for age, sex and KTR, CRP 
was still more strongly associated with frailty (β 0.15, p < 0.001). Please see Study 
III: Table 4, p. 33. 
Kynurenines as Predictors of All-Cause Mortality 
Following adjustment for age, sex, GFR and plasma CRP, increased Trp 
concentrations were associated with lower all-cause mortality, whereas increased QA 
and KTR concentrations were associated with higher all-cause mortality in MCCS and 
HUSK. After adjusting for age, sex, GFR and KTR, increased CRP concentrations 
were also associated with increased all-cause mortality in both cohorts (Table 6 on the 





Table 6. Associations of Kynurenines, and CRP with All-Cause Mortalitya 
  
Metabolites Cohortb HR 95% CI p  HR 95% CI p 
  
Unadjusted for KTRc  Adjusted for KTRc 
CRP HUSK 1.10 [1.05, 1.16] <.001**  1.06 [1.00, 1.11] .039* 
 MCCS 1.21 [1.09, 1.34] .001*  1.20 [1.09, 1.34] <.001** 
  
Unadjusted for CRPc  Adjusted for CRPc 
Trp HUSK 0.90 [0.85, 0.95] <.001**  0.91 [0.86, 0.96] <.001** 
 MCCS 0.86 [0.78, 0.96] .006*  0.87 [0.78, 0.97] .006* 
Kyn HUSK 1.11 [1.05, 1.18] <.001**  1.09 [1.03, 1.16] .004* 
 MCCS 1.06 [0.92, 1.24] .356  1.01 [0.87, 1.20] .534 
HK HUSK 1.13 [1.07, 1.19] <.001**  1.10 [1.05, 1.17] <.001** 
 MCCS 1.09 [0.96, 1.24] .172  1.05 [0.93, 1.20] .424 
KA HUSK 1.05 [0.98, 1.11] .140  1.05 [0.99, 1.11] .138 
 MCCS 1.06 [0.94, 1.18] .322  1.05 [0.94, 1.18] .368 
AA HUSK 1.10 [1.04, 1.16] <.001**  1.09 [1.03, 1.15] .001* 
 MCCS 1.12 [0.99 1.26] .060  1.11 [0.98, 1.25] .102 
XA HUSK 0.94 [0.89, 0.99] .019*  0.95 [0.90, 1.00] .044* 
 MCCS 0.96 [0.86, 1.06] .407  0.96 [0.86, 1.06] .405 
HAA HUSK 0.95 [0.91, 1.01] .100  0.95 [0.90, 1.00] .046* 
 MCCS 1.10 [0.97, 1.24] .645  1.05 [0.93, 1.20] .086 
PIC HUSK 1.00 [0.95, 1.05] .926  1.00 [0.95, 1.06] .897 
 MCCS 1.08 [0.96, 1.21] .187  1.06 [0.95, 1.19] .300 
QA HUSK 1.15 [1.09, 1.22] <.001**  1.14 [1.07, 1.20] <.001** 
 MCCS 1.30 [1.14, 1.48] <.001**  1.25 [1.09, 1.43] .002* 
KTR HUSK 1.23 [1.16, 1.30] <.001**  1.21 [1.14, 1.28] <.001** 
 MCCS 1.15 [1.02, 1.30] .022*  1.13 [1.01, 1.34] .043* 
Note: Effect sizes indicate the hazard ratio associated with a one standard deviation increase in the log-transformed 
metabolite concentrations. 
Abbreviations: AA, anthranilic acid; 95% CI, 95% confidence interval; CRP, C-reactive protein; HAA, 3-hydroxyanthranilic 
acid; HK, 3-hydroxykynurenine; KA, kynurenic acid; KTR, kynurenine to tryptophan ratio; Kyn, kynurenine; PIC, picolinic acid; 
QA, quinolinic acid; Trp, tryptophan; XA, xanthurenic acid.  
a Cox proportional hazard analysis with age, sex, and estimated glomerular filtration rate as covariates in all models, with or 
without adjustment for CRP for the kynurenines, or KTR for CRP.  
b HUSK, Hordaland Health Study (n = 3161); MCCS, Melbourne Collaborative Cohort Study (n = 970). 
c CRP adjusted for KTR. Trp, Kyn, HK, KA, AA, XA, HAA, PIC, QA, and KTR adjusted for CRP.  
* p < 0.05; ** p < 0.001. 








In this thesis, we aimed to assess whether the kynurenines were associated with 
cognitive test performance in community-dwelling persons (study I), five year 
cognitive and neuropsychiatric prognosis in mild dementia (study II), and aging 
(study III). In study I, higher plasma concentrations of KTR and neopterin were 
associated with reduced cognitive performance. Kyn, however, had a non-linear 
quadratic association with cognitive performance. In study II, investigating AD and 
LBD patients with mild dementia, we also found a non-linear quadratic association 
between serum Kyn and cognitive performance. However, Kyn was not associated 
with the rate of cognitive decline. Our findings in studies I and II suggest that 
homeostatic Kyn concentrations around the geometric mean may benefit cognitive 
function where both high and low concentrations were associated with poorer 
cognitive performance. Patients with mild dementia who had a higher serum KKR had 
increasing neuropsychiatric symptoms over five years. Study III focused on repeated 
measurements of the kynurenines in plasma, serum and CSF. In two longitudinal 
cohorts, plasma Kyn, KTR, HK, KA, and QA were positively associated with age and 
displayed consistent longitudinal changes over time. In contrast, plasma Trp was 
negatively associated with age and consistently decreased over time. Kyn, HK, KA, 
HAA, QA, KTR, and CRP were all associated with frailty in HUSK. Higher QA, 
KTR, and CRP concentrations were independently associated with higher all-cause 
mortality in both MCCS and HUSK. In contrast, higher Trp concentrations were 
associated with lower mortality. Kyn, KA and QA correlated more strongly with age 
in the CSF compared to serum. Kyn and QA consistently increased in the CSF over 
four years. Overall, our results indicate that the kynurenine pathway is significantly 
altered by aging, has a complex relationship with cognitive performance, and relates to 
the risk of neuropsychiatric symptoms in mild dementia. The immunomodulatory and 
neuroactive properties of the kynurenines highlight the importance of investigating 




SYSTEMIC AND CEREBROSPINAL FLUID CONCENTRATIONS 
An important question is whether peripheral concentrations of the kynurenines reflect 
brain concentrations, as studies I and II focused on plasma and serum measurements. 
In study III, we found a strong correlation between QA in serum versus CSF (Rs, 
0.78) and a moderate-to-strong correlation between Kyn in serum versus CSF (Rs, 
0.68) among patients undergoing elective surgery. For HK, this correlation was 0.40, 
for KA 0.28, for AA 0.38, and for PIC 0.70 (HAA and XA concentrations in CSF were 
below the limit of detection when analyzed using liquid chromatography-tandem mass 
spectrometry). The results are in line with previously identified serum-CSF 
correlations for kynurenines in inflammatory- 131  and neurodegenerative disease. 132 
We also found a weak correlation between serum and CSF Trp (Rho, 0.26), similar to 
findings in patients with multiple sclerosis. 133 Trp, Kyn, and HK are transported 
across the BBB, while KA and QA must be synthesized in the brain, mainly within 
astrocytes and microglia, respectively (see the introduction, p. 24). 10 Thus, according 
to results from study III and previous reports, the correlations between serum and 
CSF are strong for Kyn, PIC and QA, but are weak to moderate for other kynurenines.  
THE KYNURENINE PATHWAY AND COGNITIVE FUNCTION 
Cognitive Performance in Community-Dwelling Older Adults 
In study I, we aimed to investigate associations between kynurenine metabolites in 
plasma and cognitive performance in community-dwelling older adults. We found that 
higher concentrations of KTR and neopterin were associated with lower cognitive test 
performance. Specifically, higher KTR and neopterin were associated with lower test 
performance on the two cognitive tests KOLT and COWAT. KOLT is designed to 
assess memory performance and dementia status among non-institutionalized    
elderly. 134 COWAT has been used to assess the cognitive domains of language and 
executive function. However, there is no clear consensus on which interpretation is 
correct, as cognitive domains are not mutually exclusive constructs. 104 Previous 




end-stage renal disease 54 (n = 27) and patients undergoing cardiac bypass and thoracic 
surgery (n = 56). 53 Both of these studies found that higher concentrations of Kyn, KA, 
KTR, and neopterin were associated with reduced cognitive function. Even though the 
results are similar to those in our study, the presence of chronic inflammation in these 
sick individuals and somewhat different cognitive test protocols limit the 
comparability with our study. 53,54 Our findings indicate that associations between the 
kynurenines, neopterin and cognition are not only present in patients with relatively 
severe disease but also in community-dwelling older adults.  
Immune Activation as a Potential Confounder 
Clinical and experimental studies have investigated relationships between 
inflammation and cognitive function. Inflammation activates the kynurenine pathway 
and is thus a potential confounder in our study (for details, see also introduction p. 22-
23 and 30). Peripheral pro-inflammatory mediators, such as tumor necrosis factor-α, 
interleukin-6, and CRP, are associated with reduced cognitive performance in healthy 
persons. 135-139 Although study I lacked comprehensive immune profiling, CRP did not 
confound the identified associations. The main activator of the kynurenine pathway, 
IFN-γ, activates both the rate-limiting enzyme, IDO, and GTP cyclohydrolase I 
catalyzing the synthesis of neopterin in monocytes. IFN-γ knockout mice show 
improvements in neurogenesis, synaptic plasticity, and cognitive performance. 140 
Thus, higher concentrations of the kynurenines could be indirect markers of 
underlying immune activation.  
Previous Experimental Studies on Cognition 
Experimental researchers have previously investigated whether there is a link between 
changes in Trp, the kynurenines, and cognitive function. One study investigating acute 
Trp depletion identified subsequent impairment in episodic memory among mice. 141 
In an animal model of sepsis, IDO knockout mice did not show inflammation-induced 




pharmacological inhibition of KAT II, which catalyzes the conversion of Kyn to KA, 
improved both spatial discrimination and contextual memory in rats. 142  
Further, studies of rats indicate that neurons within the hippocampus, striatum, and 
neocortex are sensitive to higher QA concentrations. 49 These experimental studies 
suggest that under certain conditions, manipulation of the kynurenine pathway can 
alter cognitive function. However, it is not known whether the kynurenines are 
involved in normal cognitive function.  
Summary of Study I 
In study I, we identified associations between the kynurenines and cognitive 
performance, in agreement with previous studies, and identified a non-linear quadratic 
association between the key metabolite Kyn and cognitive performance. This indicates 
that both high and low Kyn concentrations are associated with poor cognitive 
performance, whereas concentrations around the geometric mean (i.e., the mean on the 
log-scale) are associated with better cognitive performance. Although some circulating 
kynurenines are moderately-to-strongly correlated with CSF concentrations, including 
the CSF of healthy persons would add significantly to our work. However, due to the 
risk of lumbar puncture, such studies are not easy to perform. In addition, our results 
were only adjusted for CRP, so underlying immune activation is a potentially 
unidentified confounder. Further experimental studies are needed to establish whether 
the kynurenine pathway plays a role in cognitive function under physiological 
conditions.   
THE KYNURENINE PATHWAY IN MILD DEMENTIA 
Kynurenines and Cognitive Performance  
In study II, we first aimed to determine associations between serum concentrations of 
the kynurenines and cognitive performance over five years. We found that Kyn had a 
non-linear relationship with cognitive function where both low and high levels were 




with AD or LBD (study II). A similar non-linear relationship was also seen in 
community-dwelling older adults (study I). A previous cross-sectional study identified 
that higher QA was associated with lower cognitive function in elderly patients with 
AD. 60 Kyn concentrations are tightly regulated 9 and higher Kyn concentrations may 
reflect an inflammatory state and increased IDO-activity. 143 Low substrate availability 
of Kyn may lead to reduced production of downstream neuroactive kynurenines such 
as KA and QA, and of NAD+. 144 Although it is not clear from our data why the 
association between Kyn and cognitive performance was non-linear, Kyn 
concentrations around the geometric mean may reflect more homeostatic conditions. 
Animal Models and Cell Studies on Neurodegeneration 
The kynurenine pathway has been studied in animal models and cell studies of 
neurodegenerative disease. In AD knockin mice, cerebral injection of the IDO 
inhibitor coptisine resulted in less neuronal loss, reduced amyloid plaque formation, 
and improved cognition, suggesting that IDO activation could be detrimental in AD. 4 
Experimental studies on astrocytes, microglia, and hippocampal neurons have found 
increased immunoreactivity for IDO and QA in the brains of AD patients post-
mortem. 145 Studies on cell cultures of human neurons suggest that higher 
concentrations of QA lead to increased tau phosphorylation. 49 In both human neurons 
and mouse models, elevated Aβ induces the expression of enzymes of the kynurenine 
pathway, likely by increasing IFN-γ. 146 Thus, findings from both animal models and 
human cell studies suggest on the one hand that amyloid deposits can activate the 
kynurenine pathway, and on the other hand, that increased activity of the kynurenine 
pathway may promote disease progression. 
Kynurenines and Neuropsychiatric Symptoms 
In study II, we further aimed to determine associations between serum concentrations 
of the kynurenines and neuropsychiatric symptoms over five years. The primary 
outcome was the total score from the twelve domains of the NPI with individual items 




and include hallucinations, delusions, aggression, disinhibition, depression, anxiety, 
and aberrant motor behavior. 65 We found that higher serum KKR was associated with 
increasing neuropsychiatric symptoms over five years in patients with mild dementia. 
A higher KKR reflects a relatively higher KA compared to Kyn, which may suggest 
higher enzyme activity of KATs. 9 Investigating individual domains, KKR was 
associated with increasing hallucinations over five years, whereas higher KA was 
associated with more hallucinations overall without affecting the rate of change. We 
have not identified any previous studies investigating neuropsychiatric symptoms and 
the kynurenine pathway in dementia.  
Kynurenic Acid and Previous Studies on Psychotic Disorders 
Previous studies have found associations between the kynurenine pathway and major 
psychiatric disorders, including schizophrenia and bipolar disorder. 52 Compared to 
healthy volunteers, patients with schizophrenia display higher KA concentrations in 
the CSF 147 and the prefrontal cortex following neuropathological examination. 148 
Similarly, patients with bipolar disorder with psychotic symptoms have elevated CSF-
KA, 52 with increased Kyn and KA in the anterior cingulate cortex on post-mortem 
examination. 149 Notably, KMO expression is lower in patients with schizophrenia and 
bipolar disorder with psychotic symptoms, potentially contributing to increased 
conversion of Kyn to KA. 52 Thus, our findings highlighting the potential relevance of 
the relationship between Kyn and KA for neuropsychiatric symptoms in mild dementia 
are in line with findings from studies on patients with psychosis from major 
psychiatric disorders. 
Several studies have addressed whether KA can be mechanistically linked to 
psychosis. KA is a regulator of dopaminergic and glutamatergic neurotransmission and 
an antagonist of the NMDAR, the latter a feature with the potential to trigger 
psychosis. 150 Furthermore, KA is an agonist for the AhR and an antagonist for the 
α7nAChR, linked to schizophrenia. 151,152 An increase in KA may decrease the levels 
of the neurotransmitters glutamate, 153 dopamine, 154  and acetylcholine. 155 The diverse 




symptoms and impair executive functioning. 10 Taken together, research investigating 
how KA affects neurotransmitter systems suggests that the metabolite may be of 
pathophysiological relevance to psychosis although there is as of yet no evidence from 
clinical trials in humans. 
Summary of Study II 
Study II was limited by lack of CSF measurements and lacked measures on pro-
inflammatory activation, a potential confounder. Overall, our results suggest that Kyn 
has a complex relationship with cognition but is not associated with the rate of 
cognitive decline. Further, our findings indicate that higher KA and KKR, potentially 
related to KAT activity, could be biomarkers of an increased risk of neuropsychiatric 
symptoms in mild dementia.  
THE KYNURENINE PATHWAY AND HUMAN AGING  
Associations Between Circulating Kynurenines and Age 
In study III, we aimed to assess the relationship between the kynurenines and age 
using cross-sectional and longitudinal measurements in serum, plasma and CSF. Trp 
concentrations in plasma were inversely associated with age, whilst Kyn, QA, and 
KTR were positively associated with age in two independent cohorts (MCCS and 
WENBIT) with repeated measurements of kynurenines. These associations with age 
were consistent with changes in the same metabolites over time. Similarly, 
community-dwelling older adults 74-years old had lower plasma Trp and higher HK, 
QA, and KTR compared to those 71 years of age (study III). Our findings corroborate 
findings from previous cross-sectional studies investigating associations between the 
kynurenine pathway and human aging. Generally, these studies identified lower Trp 
with older age, in different populations. 72-74,76-78 For example, Capuron et al78 included 
non-institutionalized participants aged 65 years and older, whilst Collino et al76 
enrolled centenarians and their off-spring. Further, studies investigating serum or 




Kyn, 75,78 KTR, 75,78,91, HK, KA, and AA. 75 Collectively, these clinical findings across 
diverse populations suggest that aging is associated with increased systemic activity of 
the kynurenine pathway. The observations suggest that Trp is converted to 
downstream kynurenines with the most notable increases in Kyn and QA. 
Aging rats displayed an increase in Kyn, KA, PIC, and QA with age both 
peripherally and in the brain, accompanied by increased IDO and decreased QPRT 
gene expression in the liver and brain. 156 QPRT is involved in the de novo synthesis of 
NAD+, which is reduced in aging and neurodegenerative disorders. 157 Inhibition of 
QA degradation, as observed in aging rats, could serve as a potential explanation for 
the relative abundance of QA, compared to other kynurenine metabolites, with aging 
(study III).  
The kynurenine pathway is activated by pro-inflammatory cytokines, which 
increase with aging. Trp typically decreases with inflammation, as IDO catalyzes the 
formation of Kyn and downstream kynurenines. 2 IFN-γ stimulation of human 
monocytes ex-vivo results in increased concentrations of QA and KTR. 158 Aged 
macrophages have higher IDO-activity and produce more cytokines. 32 This suggests 
that increased pro-inflammatory activation associated with aging, or inflammaging, 
could contribute to increased conversion of Trp to kynurenines. This could in turn 
affect the immune system. Furthermore, higher IDO expression in breast cancer has 
been linked to immune evasion and poor outcomes. 159 A lack of Trp and an increase 
in Kyn concentrations likely suppress CD8+ and CD4+ T-cells via amino acid sensing 
signals and the AhR. 2,160-162 CD4+ and CD8+ CD28- T-cells, increase with age, whilst 
Tregs are depleted. 163 The immunomodulatory effects of low Trp and high Kyn could 
thus serve to constrain inflammaging. 2 However, our study cannot determine whether 
activation of the kynurenine pathway in human aging is harmful or adaptive.  
The kynurenine pathway is involved in energy metabolism through the conversion 
of its end-product QA to NAD+ in a reaction catalyzed by QPRT. Declining levels of 
NAD+ is observed across multiple species with aging, and this phenotype of aging is 




concentrations in multiple organs, including brain, liver, muscle, pancreas, adipose 
tissue, and skin. An age-dependent reduction of NAD+ has also been identified in C. 
elegans and aged human tissue. 164 This apparent discrepancy where QA increases 
with age in our study while NAD+ decreases with age 157 could be explained by 
reduced QPRT activity, which has been identified in an animal study of aging. 156 
Accordingly, it is plausible that both the well-known reduction in micronutrient intake 
observed with aging 165 and reduced conversion of QA contributes to age-related 
NAD+ deficiency, 157 a topic for future studies. 
Aging and Kynurenines in the Cerebrospinal Fluid 
We further aimed to assess associations between kynurenines in CSF and age using 
data from COGNORM. Kyn and QA displayed stronger correlations with age in CSF 
compared to serum. Kyn and QA, and marginally HK, also increased in the CSF over 
time. CSF-QA was most strongly correlated with age, doubling in the fourth versus the 
first age quartile, and increased the most over time. There was no significant change in 
Trp, KA, AA, and PIC in the CSF over time, and CSF concentrations of HAA and XA 
were below the limit of detection. Our findings correspond with previous cross-
sectional studies reporting a correlation between age and CSF-QA, and between age 
and CSF-KA. 74,80 Trp correlated inversely with age in serum, but positively in the 
CSF, in line with previous studies demonstrating an increase in Trp in the CSF with 
aging. 10,74 Our study, comparing serum and CSF correlations with age, suggest that 
altered activity of the kynurenine pathway may be more profound in the brain than 
systemically. 
An increase of QA in the CSF of aging individuals could be of consequence. In 
the brain, QA is mainly generated from microglia or migrating monocytes. 10 QA is 
linked to NMDAR-dependent neurotoxicity, oxidative stress, and inhibition of 
mitochondrial function. 50 Significantly, patients with neurodegenerative and 
psychiatric disorders such as schizophrenia and bipolar disorder have increased 
concentrations of kynurenines in the CSF and brain tissue. 12 Thus, increased activity 




known at which brain concentrations QA becomes clinically relevant to adverse 
outcomes. Consequently, whether QA is a relevant pathophysiological factor in age-
related, neurological, and psychiatric disorders needs to be further investigated. 
Frailty and the Kynurenine Pathway 
We further aimed to assess associations between plasma Trp, the kynurenines, and 
CRP with frailty in HUSK. Frailty is an important hallmark of pathological aging, 166 
defined as: “a state of vulnerability to adverse outcomes”. One method to measure 
frailty is by a frailty index. Its principle is to count health deficits on the basis that the 
more health deficits a person has, the frailer they are. 117 Across multiple studies, 
frailty is significantly associated with poor health outcomes and a shorter lifespan. 167 
We constructed a frailty index based on available data on health deficits in HUSK 
from community-dwelling older adults aged 71-74 years, as previously described (see 
Methods, Study III: Frailty Index, p. 42). 117 Among the kynurenines, plasma QA was 
most strongly associated with frailty, followed by Kyn and KTR. However, CRP was 
more strongly associated with frailty than any of the kynurenine metabolites. HK, KA, 
and HAA were also significant but less strongly related to frailty. These findings are 
largely consistent with the kynurenines most associated with aging in HUSK, MCCS, 
and WENBIT (Study III). Our results are also in line with previous findings on 
kynurenines and frailty, 168,169 and underscore a consistent association between QA and 
frailty. Westbrook et al168 found higher Kyn, HK, KA, QA, and KTR, and lower Trp in 
frail persons above 70 years of age compared to younger individuals. Similarly, in a 
study by Marcos-Pérez et al169 of older adults above 65, frailty was associated with 
higher KTR and neopterin concentrations and reduced Trp concentrations. Our results 
and those of previous studies suggest that the kynurenines are associated with frailty, 
although we did not find lower Trp with increasing frailty as in previous studies.   
Experimental studies have also found associations between inflammation, the 
kynurenine pathway, and frailty. In older IL-10 knockin mice, higher levels of KTR 
and reduced concentrations of Trp were associated with reduced function and loss of 




inhibitor showed an increase in the size of muscle fibers and muscle strength. 170 
Taken together, a potential role in sarcopenia in experimental studies, a hallmark of 
frail individuals, 171 adds support for a role of the kynurenine pathway in frailty. 
Mortality and the Kynurenine Pathway 
Lastly, we aimed to assess associations between Trp, the kynurenines, and CRP with 
mortality. In comparison to the other kynurenines, plasma QA and KTR displayed 
relatively stronger associations with mortality consistent in both MCCS and HUSK, 
which were independent of age, sex, renal function, and CRP. Higher plasma Trp 
concentrations were associated with enhanced survival in both cohorts. The 
associations between Kyn, HK, AA, KTR, and CRP with mortality in HUSK have 
been published previously. 172 Increased KTR has been associated with coronary 
events, cancer, frailty, and mortality in nonagenarians. 2 The kynurenine biomarkers 
most associated with aging (i.e., KTR and QA) were also the most associated with 
mortality.  
Experimental studies have identified potential links between Trp, the kynurenines, 
and longevity. In C. elegans and D. melanogaster, depletion or loss of function of 
TDO results in increased longevity. 173,174 TDO-2 knockout in C. elegans increased 
lifespan by 15%. 173 In a study encompassing 26 mammalian species, KTR was 
negatively correlated with longevity. 175  
Summary of Study III 
Overall, our results are in line with previous findings indicating altered kynurenine 
pathway activity with age. Trp decreases with age, accompanied by an increase of 
downstream kynurenines. Our study expands upon previous studies and show that 
these age-related changes are consistent with changes over time in MCCS and 
WENBIT for Trp, Kyn, HK, QA, and KTR, a critical finding to identify an aging 
biomarker. 87 Further, decreased Trp and increased KTR and QA are seen with minor 
differences in age. Higher Trp concentrations were associated with lower all-cause 




all-cause mortality. Compared to other kynurenines, QA displayed the strongest 
association with age and changed the most over time. Kyn and the potentially 
neurotoxic QA were more strongly correlated with age in the CSF than in serum, and 
increased in the CSF over a period of four years. It is unknown at which 
concentrations QA becomes clinically relevant for adverse outcomes in the brain. Still, 
it appears the aging brain could be exposed to a disproportionate increase in the 





The kynurenine pathway is connected to multiple physiological systems. Future 
studies of the kynurenine pathway in aging and age-related diseases should include 
multiple sample types, such as plasma, urine, feces, CSF, and immune cells. This 
would help provide a more complete picture. It is currently not clear whether the 
kynurenines are simply markers of immune activation or mediators between 
inflammatory activation and immune function, and potentially cognitive and 
psychiatric outcomes by way of their neuroactivity. In humans, studies including more 
detailed immune profiling with longitudinal, repeated measurements would be highly 
informative. Similarly, comprehensive metabolic profiling, including the NAD+ 
metabolome would provide information on the relationship between QA and NAD+, 
which is implicated in aging and neurodegenerative diseases. 164 
The role, if any, of the kynurenine pathway in normal cognitive function needs to 
be further investigated in otherwise healthy animals using experimental manipulation 
more reflective of the physiological condition rather than genetic knockout of 
enzymes. KAT inhibitors are being considered for clinical trials in schizophrenia 176 
and if proven effective, this could be considered for neuropsychiatric symptoms in 
dementia, as there are few, if any, available and effective treatments for patients with 
dementia and neuropsychiatric symptoms. 177  
There are indeed numerous ways of intervening therapeutically to target enzymes 
of the kynurenine pathway, each with its challenges. The depletion of Trp with aging 
suppresses T-cell proliferation, and theoretically, replenishing Trp could improve the 
immune response. However, higher substrate availability may also lead to an increase 
in downstream neuroactive and immunomodulatory metabolites. 9 Analogues of 
neuroprotective kynurenines or KMO inhibitors aim to skew the balance of 
kynurenines towards neuroprotection and are considered to hold therapeutic potential. 
However, it remains unclear whether KA displays clinically relevant neuroprotective 
effects. 12 Further, as selective NMDAR knockout is an animal model of 




clinical trials investigating psychiatric disorders or neuropsychiatric symptoms in 
dementia. KMO inhibition, like IDO inhibitors, may lead to an excessive reduction of 
QA, which functions as a precursor of NAD+. Accordingly, concomitant NAD+ 
supplementation might be pertinent. 11 KMO inhibition may elevate peripheral Kyn 
levels, which can be converted to QA in the brain after crossing the BBB. Therefore, 
an efficient KMO inhibitor would require sufficient brain penetrance for therapeutic 
efficacy. 12 This could be avoided with an IDO inhibitor, which inhibits the formation 
of Kyn, the main precursor of brain kynurenines. IDO inhibitors have been 
investigated in cancer research, and may potentiate the efficacy of chemotherapy, and 
promote tumor regression, but these mechanisms remain unclear. 178 In addition, 
clinical and experimental studies suggest KAT inhibitors to reduce brain KA 
concentrations as a new therapeutic approach for cognitive and psychotic disorders. 
However, no randomized trials have been conducted to date. 52 All told, further 
research investigating the kynurenine pathway has the potential to result in novel and 
more effective treatments for multiple diseases. However, due to the kynurenines’ 
complex relationship with numerous biological pathways and organ systems, this is 






STRENGHTS AND LIMITATIONS 
The research included in this thesis has several strengths. We included five 
independent cohorts from different populations, with cross-sectional and longitudinal 
data. Several of the cohort studies had relatively large sample sizes (MCCS, HUSK, 
WENBIT), which increase the statistical power of our analyses. We performed 
comprehensive, targeted metabolomic profiling of the kynurenines in serum, plasma, 
and CSF using a centralized laboratory for all analyses. The HUSK study had a 
relatively high response rate among the participants, and they were of similar age (71-
74 years old), which limits the impact of age itself on metabolites and cognition (study 
I). Further, the DemVest study had a longitudinal design with annual follow-up 
examinations until death, combined with a low dropout rate amongst the patients who 
survived five years of follow-up (study II). In addition, the COGNORM performed 
repeated CSF sampling of patients who underwent elective surgery (study III). 
This thesis also has several limitations. General limitations include a lack of 
ability to identify causal relationships, common to all observational studies. Multilevel 
models assume that missing data follow the missing at random assumption. This 
means that persons with missing data can be characterized by observed data rather 
than unobserved data. This statistical assumption is not easily testable and may bias 
the results. The frailty analysis was performed under the assumption that the data were 
missing completely at random, increasing the risk of bias (study III). The relatively 
small sample size in study II is associated with a higher risk of bias compared to 
studies I and III as the normality assumptions are less likely to hold. The kynurenine 
metabolites are intercorrelated. It is therefore difficult to ascertain whether 
associations represent single metabolites or more broad activities in the metabolic 
pathway. Statistical transformation assures that the assumption of normality, a 
prerequisite of most multivariable models, is not violated but unfortunately 





This thesis included five independent cohorts with comprehensive kynurenine 
metabolite measurements. However, the sampling was non-standardized and 
metabolite differences between cohorts may relate to variation in follow-up times, 
blood sampling, and time to censoring. As Trp is an essential amino acid, non-fasting 
blood samples is a limitation in DemVest, HUSK, WENBIT and among a proportion 
of MCCS samples. CSF measurements in studies I and II would have been 
informative, as only Trp, Kyn, and HK are transported across the BBB. The absence of 
a suitable control group is a further limitation in study II. 
There are limitations related to the assessment of cognitive function, depression, 
and neuropsychiatric symptoms in this thesis. When measuring cognitive function, 
cognitive domains are not mutually exclusive, which can make interpretation of 
cognitive test results challenging, as one test may measure multiple cognitive domains 
such as language, memory, and executive function (studies I and II). Further, the 
HADS is not a diagnostic test for depression (study I). In addition, we used 
antidepressants as a surrogate marker for depressive symptoms, but these medications 
have several other indications, such as treatment of anxiety and sleep disturbances. 
Patients with major depression are also less likely to participate in studies (study I).  
Finally, at present there is no clear consensus on how to best measure frailty, but 
the frailty index has been validated in several studies. 117 In comparison, previous         
studies 168,169 have measured frailty using the validated frailty screening tool by Fried 
et al179, which consists of grip strength, walking speed, and questions concerning 
fatigue, weight loss, and physical activity. It is not clear whether the use of the Fried 
screening tool or an alternative frailty scale would have changed the associations we 







1. Plasma KTR and neopterin were associated with lower cognitive function in the 
domains of memory and language in community-dwelling older adults. 
2. There were no associations between serum kynurenine pathway metabolites at 
baseline and cognitive prognosis in patients with mild dementia. 
3. The relationship between Kyn and cognition was non-linear in community-
dwelling persons and patients with mild dementia. Kyn concentrations around 
the geometric mean were associated with better cognitive performance whereas 
low and high concentrations were associated with poorer cognitive 
performance. 
4. Higher KKR was associated with more neuropsychiatric symptoms over time in 
patients with mild dementia.  
5. Kyn, HK, KA, and most notably QA and KTR were positively associated with 
age and increased over time, whereas Trp was inversely associated with age and 
decreased over time.  
6. Kyn and the potentially neurotoxic QA were more strongly correlated with age 
in the CSF than in serum.  
7. Several kynurenines, most notably QA, Kyn, and KTR were associated with 
frailty. Higher Trp concentrations were associated with lower all-cause 
mortality, whereas higher QA and KTR concentrations were associated with 
higher all-cause mortality in two independent cohorts. 
8. Kynurenines were better biomarkers of chronological age compared to CRP and 
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Kendrick Object Learning Test
Controlled Oral Word Association Test
A B S T R A C T
Introduction: Tryptophan, its downstream metabolites in the kynurenine pathway and neopterin have been as-
sociated with inflammation and dementia. We aimed to study the associations between plasma levels of these
metabolites and cognitive function in community-dwelling, older adults.
Methods: This cross-sectional study included 2174 participants aged 70–72 years of the community-based
Hordaland Health Study. Tryptophan, kynurenine, neopterin and eight downstream kynurenines were measured
in plasma. Kendrick Object Learning Test (KOLT), Digit Symbol Test (DST) and the Controlled Oral Word
Association Test (COWAT) were all outcomes in standardized Zellner’s regression. The Wald test of a composite
linear hypothesis of an association with each metabolite was adjusted by the Bonferroni method. Age, body mass
index, C-reactive protein, depressive symptoms, diabetes, education, glomerular filtration rate, hypertension,
previous myocardial infarction, prior stroke, pyridoxal 5′phosphate, sex and smoking were considered as po-
tential confounders.
Results: Higher levels of the kynurenine-to-tryptophan ratio (KTR) and neopterin were significantly associated
with poorer, overall cognitive performance (p < 0.002). Specifically, KTR was negatively associated with KOLT
(β −0.08, p= 0.001) and COWAT (β −0.08, p=0.001), but not with DST (β −0.03, p=0.160). This pattern
was also seen for neopterin (KOLT: β −0.07; p= 0.001; COWAT: β −0.06, p=0.010; DST: β −0.01,
p= 0.800). The associations were not confounded by the examined variables. No significant associations were
found between the eight downstream kynurenines and cognition.
Conclusion: Higher KTR and neopterin levels, biomarkers of cellular immune activation, were associated with
reduced cognitive performance, implying an association between the innate immune system, memory, and
language.
1. Introduction
Tryptophan (TRP), an essential amino acid, is degraded primarily
through the kynurenine pathway (KP, Fig. 1) which generates meta-
bolites collectively referred to as the kynurenines (Chen and Guillemin,
2009). TRP and the kynurenines have been related to cognitive im-
pairment (Baran et al., 1999), cardiovascular disease (Sulo et al., 2013;
Zuo et al., 2016), renal function (Theofylaktopoulou et al., 2013), in-
flammation, obesity, diabetes and psychiatric disorders (Cervenka
et al., 2017). However, a relationship between the kynurenines and
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cognitive function in a community-dwelling cohort has not been es-
tablished.
Reduced levels of circulating TRP and several kynurenines have
been found in persons with dementia compared to controls (Giil et al.,
2017), while elevated levels of anthranilic acid (AA), a derivative of
kynurenine (KYN), has been linked to dementia in a prospective study
(Chouraki et al., 2017). In cognitively healthy persons, elevated levels
of inflammatory mediators are linked to poor cognitive performance
(Smith et al., 2012). The kynurenines are closely linked to the innate
immune system and have immune regulatory actions (Hwu et al.,
2000). During an inflammatory state, cytokines stimulate the activity
and expression of indoleamine 2, 3-dioxygenase (IDO), which converts
TRP to KYN, mostly in monocytes. This leads to reduced TRP and an
increase in downstream kynurenines, especially KYN (Capuron et al.,
2011). The most important activator of IDO is interferon-γ (IFN-γ),
which also activates GTP-cyclohydrolase I (GTP-CH), the rate-limiting
enzyme in the biosynthesis of neopterin, which is a pteridine produced
by monocytes during inflammation (Wirleitner et al., 2002). Increased
levels of neopterin have been linked to dementia (Parker et al., 2013).
IDO is also expressed in the brain and may have importance in the
relationship between systemic inflammation and cognitive impairment
(Comim et al., 2017). Inflammation activates IDO and may increase
levels of neurotoxic kynurenine metabolites in the brain with potential
harmful effects on the hippocampus (Lim et al., 2013; Schwarcz and
Kohler, 1983). Further, TRP and KYN pass the blood-brain barrier (BBB)
(Fukui et al., 1991; Smith et al., 1987) and are key substrates for the
brain’s synthesis of serotonin and kynurenines (Chen and Guillemin,
2009).
Our aim was to study the relationship between circulating levels of
TRP, kynurenines, and neopterin with cognitive test performance in a




Study participants were included from HUSK, conducted in
Hordaland County, Western Norway (http://husk-en.w.uib.no). Details
of the recruitment procedures in both the main study and the cognitive
sub-study have been described previously (Nurk et al., 2007). Briefly,
from the source cohort, 2841 participants born in 1925–27, living in
Bergen and three surrounding municipalities, were invited by letter to
participate in HUSK during 1997 to 1999. Of these, 2197 participants
(77.3%) were included in the sub-study on cognitive function and of
these, 2174 had available blood samples and were included in the
present study. The presence of disease was not an exclusion criterion in
this population-based cohort. The self-reported prevalence of hy-
pertension was 32.8%, previous myocardial infarction 10.6%, diabetes
6.7%, and prior stroke 4.7% (Table 1). The Regional Committee for
Medical and Health Research Ethics approved the study protocol (REC
number: 2016/2208) and all participants provided signed informed
consent.
2.2. Measurement of metabolites
Non-fasting blood samples were collected at baseline, and aliquots
of EDTA plasma samples were stored at −80 ◦C until analysis. TRP,
eight kynurenines (KYN, AA, kynurenic acid (KA), 3-hydro-
xykynurenine (HK), 3-hydroxyanthranilic acid (HAA), xanthurenic acid
(XA), picolinic acid (PIC), quinolinic acid (QA)), pyridoxal 5′ phosphate
(PLP), neopterin and cotinine were measured using liquid chromato-
graphy-tandem mass spectrometry (Midttun et al., 2009). In general,
the kynurenine metabolites remain stable under long-term cryopre-
servation. TRP, KYN, KA, XA, PIC and QA remain stable. Under non-
optimal preanalytical handling or storage, HK and HAA may decrease,
while AA may increase (Hustad et al., 2012). However, all these three
markers were within their normal concentration range in our study
(Midttun et al., 2017). The ratio between kynurenine and tryptophan
was calculated as KYN (µM)/TRP (µM) * 100. The limit of detection was
0.4 µmol/L for TRP, while for neopterin and the kynurenines, limits of
detection ranged from 0.5 nmol/L to 7 nmol/L. Within-day and be-
tween-day coefficients of variation were 3.0–9.5% and 5.7–16.9%, re-
spectively.
Plasma high-sensitivity C-reactive protein (CRP) level was de-
termined using an immune-MALDI (matrix-assisted laser desorption/
ionization) mass spectrometry method (Meyer and Ueland, 2014). For
CRP, the limit of detection was 0.2 µg/L, and within-day and between-
day coefficients of variation were 5.5–8.4% and 7.0–11.7%, respec-
tively. All biochemical analyses were performed in the laboratory of
Bevital AS (http://bevital.no).
Fig. 1. The kynurenine pathway. TDO and IDO
converts tryptophan to kynurenine. HK is converted
to 3-hydroxyanthranilic acid (HAA) by kynureninase
(KYNU), and subsequently to quinolinic acid (QA),
catalyzed by quinolinate phosphoribosyl transferase.
QA is converted to nicotinamide adenosine dinu-
cleotide (NAD), the final product of the pathway.
Anthranilic acid is produced from KYN by KYNU.
Kynurenine aminotransferases (KATs) generate KA
from KYN and xanthurenic acid (XA) from HK.
Picolinic acid is produced by spontaneous conver-
sion of HAA. Both KYNU and KATs have pyridoxal
5′-phosphate (PLP) as a cofactor (Chen and
Guillemin, 2009). HAA, 3-hydroxyanthranilic acid;
HK, 3-hydroxykynurenine; 3-HAO, 3-hydro-
xyanthranilic acid 3, 4-dioxygenase; IDO, in-
doleamine 2, 3-dioxygenase; KATs, kynurenine
aminotransferases; KMO, kynurenine mono-
oxygenase; KTR, kynurenine-tryptophan ratio;
NAD+, nicotine adenine dinucleotide; Spont, spon-
taneous; TDO, tryptophan 2, 3-dioxygenase.
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2.3. Testing of cognitive function
We identified ceiling effects in both a brief version of the Mini-
Mental Status Examination and Block-Design (supplementary materials,
Figure S1). This implies that the true level of cognitive function has not
been accurately measured in the participants who reached the ceiling
effects. Further, the Trail Making Test A displayed a log-normal dis-
tribution with a bimodal trend. These cognitive tests were therefore
considered unsuitable as measurements of cognitive function.
The following normally distributed tests, which indicates an ap-
propriate difficulty level with a centralized mean, were selected to
describe cognitive function: Kendrick Object Learning Test (KOLT), the
Controlled Oral Word Association Test (COWAT), and the Digit Symbol
Test (DST) (Nurk et al., 2007). Briefly, KOLT measures immediate recall
and requires participants to observe picture charts, before telling the
examiner what they observed (Kendrick, 1985). DST evaluates execu-
tive function and is performed by completing a coding table that
consists of the numbers 1–9 and symbols. Participants are instructed to
fill in blank squares with the symbol that is paired with the digit dis-
played above the square (Wechsler, 1981). Lastly, COWAT encourages
participants to write as many words as possible beginning with a given
letter in 60 s and is considered a measure of language, memory, and
executive function (Benton A, 1989). Thus, the cognitive domains of
memory, language, and executive function were examined in this study.
2.4. Potential confounders
Age, gender and educational attainment (Ngandu et al., 2007) were
adjusted for. Cardiovascular disease (Zuo et al., 2016), diabetes (Stone
and Darlington, 2002) and stroke (Darlington et al., 2007) have been
associated with both kynurenines and cognitive performance (Biessels
et al., 2008; Stampfer, 2006; Tatemichi et al., 1994). Similarly, a high
body mass index (BMI) is associated with higher levels of kynurenines
(Mangge et al., 2014) and poor cognition (Cournot et al., 2006). PLP is
a coenzyme in the kynurenine pathway and associated with in-
flammation and cognitive function (Kennedy, 2016). Renal function
determines kynurenine levels (Pawlak et al., 2002) and poor renal
function is associated with cognitive dysfunction (Seliger et al., 2004).
The same applies to smoking (Anstey et al., 2007). Thus, estimated
glomerular filtration rate (Modification of Diet in Renal Disease equa-
tion) (Levey et al., 2006) and current smoking (plasma coti-
nine≥10 nmol/L) were adjusted for in our analyses (Seccareccia et al.,
2003).
Kynurenine levels are higher in major depression and TRP levels is
lower (Myint et al., 2007). Furthermore, depression is associated with
poor cognitive performance (Biringer et al., 2005). We aimed to es-
tablish whether kynurenines were associated with depressive symptoms
in this population-based sample. To this purpose, we applied the Hos-
pital Anxiety and Depression Scale (HADS) and defined a score of≥8 as
an indicator of mild depressive symptoms, in accordance with Stern
et al. (Stern, 2014). HADS questionnaires with one or two missing an-
swers on the items examining depressive symptoms were imputed as
the mode of the other answers (N=122). A total of 234 participants
who underwent cognitive testing did not answer the HADS ques-
tionnaire. To further characterize if TRP and kynurenines were related
to depressive symptoms in this study, we used antidepressant agents as
a surrogate marker. Anti-depressive medications were categorized ac-
cording to the 1997 ATC-classification system and included all agents
under N06A (selective serotonin reuptake inhibitors, tricyclic and tet-
racyclic antidepressants) and NX5 (selective norepinephrine reuptake
inhibitors). Further, we investigated if the use of non-steroidal anti-
inflammatory drugs (NSAIDs) were associated with kynurenine levels.
If so, these would be included in the multivariate models. NSAIDs were
defined by the 1997 ATC-registry groups M01A and N02B.
Finally, CRP is of special interest, as it is one of the most frequent
measures of inflammation reported as a negative determinant of cog-
nitive performance. Innate immune activation is expected to increase
both CRP levels, and the levels of several kynurenines downstream of
TRP (Kuo et al., 2005; Zuo et al., 2016). We thus evaluated associations
between TRP, kynurenines and CRP, and adjusted any significant
findings for CRP levels.
2.5. Statistics
Prior to multivariable analysis, metabolites were transformed ac-
cording to Tukey’s ladder of Powers (Tukey, 1977). The purpose was to
linearize relationships by achieving approximately normal distribu-
tions, as assessed by histograms and quantile-quantile plots. KYN was
transformed by an inverse transformation, QA and KTR as the inverse of
the square root and KA, XA, PIC, the KA/QA ratio, PLP and neopterin by
log transformations. CRP was transformed by a Box-Cox transformation
(Box and Cox, 1964). To compare effect sizes across the scales that
arose from the use of transformations, all continuous covariates and
Table 1
Demographic and clinical characteristics.
Variable Statistic
Demographics and general health
Age, years, median [range] 71 [70–72]
Women, % 55.2
Education, %
<7 years of Primary School 7.3
7–10 years of Primary School 31.6
1–2 years of High School 30.2
3 years of High School 11.9
College/University 19.0
Diabetes, % 6.7
Current smokinga, % 17.8
eGFR, mL/min/1.73m2, mean [SD] 71.7 [15.7]








KOLT score, mean [SD] 35 [8.1]
COWAT score, mean [SD] 15 [5.5]
DST score mean [SD] 10 [4.2]
Metabolite levels
TRP, µmol/L, median [IQR] 67.8 [17.5]
KYN, µmol/L, median [IQR] 1.72 [0.50]
KA, nmol/L, median [IQR] 54.8 [25.2]
AA, nmol/L, median [IQR] 16.0 [7.20]
XA, nmol/L, median [IQR] 16.4 [10.0]
HK, nmol/L, median [IQR] 36.1 [15.5]
HAA, nmol/L, median [IQR] 35.0 [17.0]
PIC, nmol/L, median [IQR] 49.4 [28.1]
QA, nmol/L, median [IQR] 462 [2 2 6]
Neopt, nmol/L, median [IQR] 8.70 [3.30]
PLP, nmol/L, median [IQR] 49.1 [44.5]
KTR, µmol/L/ µmol/L*100, median [IQR] 2.50 [0.70]
KA/QA, nmol/L/nmol/l*100, median [IQR] 11.87 [5.55]
a Plasma cotinine level≥ 10 nmol/l.
b ATC-classification system, NX5 and N06A: selective serotonin and nor-
epinephrine reuptake inhibitors. Tricyclic and tetracyclic antidepressants.
c ATC-registry groups M01A and N02B. AA, anthranilic acid; BMI, body mass
index; COWAT, Controlled Oral Word Association Test; DST, Digit Symbol Test;
eGFR, estimated glomerular filtration rate; HAA, 3-hydroxyanthranilic acid;
HK, 3-hydroxykynurenine; IQR, inter-quartile range; KA, kynurenic acid; KA/
QA, kynurenic acid-quinolinic acid ratio; KOLT, Kendrick Object Learning test;
KTR, kynurenine-tryptophan ratio; KYN, kynurenine; MI, previous myocardial
infarction; Neopt, neopterin; NSAIDs, non-steroidal anti-inflammatory drugs;
PIC, piconilic acid; PLP, pyridoxal 5′phosphate; QA, quinolinic acid; TRP,
tryptophan; XA, xanthurenic acid.
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outcomes were scaled to z-scores. Logistic- and linear regressions were
used to determine associations between potential confounders, kynur-
enines and outcomes.
The cognitive tests were positively correlated (supplementary ma-
terials, Figure S2) and potentially not independent outcome variables.
We first identified a highly significant Breusch-Pagan test (Breusch and
Pagan, 1979), which indicates correlated residuals from separate linear
regressions. Therefore, we decided to assess the associations between
all cognitive tests and each metabolite by Zellner’s seemingly unrelated
regression (SUR), which estimates a set of m linear regressions with
correlated error terms (Jahanshad et al., 2015). We used the two-step
estimation procedure. After initial analysis with age, gender, body mass
index, education (in years), GFR, current smoking, diabetes, previous
myocardial infarction, prior stroke and PLP, additional confounders
associated with TRP, kynurenines or neopterin, were adjusted.
It is impractical to formulate a hypothesis about which exact cog-
nitive test is related to which metabolite. Therefore, we tested the joint
significance of the association between each metabolite and “cogni-
tion”, represented by the three cognitive outcomes in SUR. In order to
test the joint significance, we applied the Wald test on a composite
linear hypothesis (Cameron, 2009), composed of the three hypotheses
of association between the metabolite and the three cognitive tests. The
joint significance (α = 0.05) threshold was adjusted for the number of
hypotheses tested, according to the Bonferroni method (Chen et al.,
2017). All statistical analyses were conducted using Stata (version 15,
Stata Corp, College Station, Texas, USA).
3. Results
3.1. Participant characteristics
A total of 2174 participants (55.2% women), aged 70–72 years with
cognitive tests and available blood samples are included in the analysis.
The mean scores and standard deviations (SD) of KOLT, DST, and
COWAT were 35 (SD: 8.1), 10 (SD: 4.2) and 15 (SD: 5.5), respectively.
KOLT, DST, and COWAT were approximately normally distributed
within the population (supplementary materials, Figure S2). Nineteen
percent of the study participants went to college or university (Table 1).
There were no major differences in the plasma concentrations of ky-
nurenines between the subgroups completing cognitive testing and the
HADS questionnaire.
3.2. Kynurenines and cognitive performance
KTR and neopterin were significantly inversely associated with
cognitive performance measured by KOLT (memory) and COWAT
(language) (Fig. 2), while no such associations were seen with DST
(executive function) (Table 2). KTR showed the strongest association
with cognitive performance (Table 2). Further, PLP was significantly
associated with DST (β 0.069, p=0.001), but did not act as a con-
founder.
3.3. Kynurenines and potential confounders
3.3.1. Depressive symptoms and antidepressant agents
TRP, KTR, the kynurenines, the KA/QA ratio and neopterin were not
associated with depressive symptoms or antidepressant agents
(Table 3). Thus, depression was not considered as a potential con-
founder for the relationship between kynurenines and cognition.
3.3.2. Non-steroidal anti-inflammatory drugs
Six percent of the participants reported use of NSAIDs (Table 1).
NSAIDs showed an association with TRP, KYN and KTR (Table 3), but
did not confound our results (Table 4).
3.3.3. C-reactive protein
CRP was associated with KYN, HK, HAA, QA, KTR, the KA/QA ratio
and neopterin (Table 3). After adjusting the SUR model for CRP, it did
not act as a confounder (Table 4).
4. Discussion
We studied cognition in relation to neopterin, tryptophan, and the
kynurenines in a community sample of older adults and found that
elevated levels of both KTR and neopterin were associated with lower
performance in the cognitive domains of memory and language. KTR
showed the strongest association.
Our study included 2174 persons (55.2% women) aged 70–72 years
recruited from a population of home-dwelling older adults. In com-
parison, other studies that have investigated the relationship between
the kynurenines, neopterin and cognitive function, have been based on
small patient groups with specific diseases. Higher levels of neopterin
and kynurenines were related to lower cognitive performance post-
Fig. 2. Cognitive tests and markers of immune ac-
tivation. Predicted results from Zellner’s regression,
adjusted for age, sex, body mass index, educational
level, estimated glomerular filtration rate, current
smoking, diabetes, hypertension, previous myo-
cardial infarction, prior stroke, and pyridoxal 5′
phosphate as covariates. COWAT, Controlled Oral
Word Association Test; KOLT, Kendrick Object
Learning Test; KTR, kynurenine-tryptophan ratio.
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operatively amongst patients who had undergone cardiac bypass sur-
gery (N=28, mean age of 60.2 years, 11% women), and major non-
cardiac thoracic surgery (N=28, mean age of 67.6 years, 32% women)
(Forrest et al., 2011). Additionally, a study of patients with stage IV
renal failure (N=27, mean age of 76.4 years, 33% women), suggested
that rising levels of neopterin and KYN were associated with lower
cognitive performance (Karu et al., 2016). Further, neopterin was as-
sociated with progression of cognitive deficits in patients with Alzhei-
mer’s disease (Blasko et al., 2007; Leblhuber et al., 1999). Previous
studies have shown that acute TRP depletion may impair episodic
memory, and suggest a role of the serotonergic system in cognitive
function (Mendelsohn et al., 2009). Our results support that the ky-
nurenine pathway may be relevant for cognitive function.
There is evidence of an association between peripheral pro-in-
flammatory mediators, such as tumor necrosis factor-α, Il-6, and CRP,
and reduced cognitive performance in healthy humans (Economos
et al., 2013; Schram et al., 2007; Teunissen et al., 2003; Wichmann
et al., 2014; Yaffe et al., 2003). Therefore, the kynurenines could rather
be indirect markers of their underlying activators, which are mainly
related to inflammation. We did not identify confounding from CRP in
our data, but a more comprehensive assessment of inflammation would
have been informative.
In this study, nine percent of the participants had depressive
symptoms (HADS score>= 8), but we found no association with TRP
or kynurenine levels. Although an association between kynurenines and
major depression has been described, our study is not comparable and
does not generalize to major depressive disorder. First, HADS is not a
diagnostic test of depression (Cosco et al., 2012; Myint et al., 2007).
Second, patients with major depression are less likely to participate as
study volunteers (Hughes-Morley et al., 2015). Finally, participants
with depressive symptoms and patients using antidepressants likely
represent a heterogeneous group, as antidepressant agents have broad
indications, for example for treating anxiety and sleeping disturbances
in the elderly (Noordam et al., 2015). Here, depressive symptoms were
mainly of interest as potential confounders.
PLP, the active form of vitamin B6, was associated with DST but did
not act as a confounder in our study. Our findings are in line with
studies indicating both a detrimental effect on cognition from PLP de-
ficiency. Vitamin B6 is actively transported over the BBB and is a rate-
limiting cofactor in the synthesis of neurotransmitters such as dopamine
and serotonin (Kennedy, 2016). Circulating PLP levels are lower in
individuals with inflammation compared to healthy subjects (Ueland
et al., 2017), and has been proposed to contribute to cognitive decline
(Kennedy, 2016). Intervention studies administering vitamin B6
Table 2
Cognitive performance and individual metabolites (N=2174).a
KOLT COWAT DST Wald testd
Memory Language Executive function
Association of each metabolite with three cognitive tests
β SE p β SE p β SE p X2 pc
TRP 0.047 0.022 0.03 0.043 0.022 0.05 0.050 0.021 0.02 9.2 0.027
KYNb -0.021 0.024 0.4 -0.030 0.024 0.2 0.026 0.023 0.3 4.6 0.2
KYN2b -0.061 0.021 0.003 -0.021 0.020 0.3 -0.044 0.020 0.03 11.3 0.01*
KA 0.022 0.026 0.4 -0.011 0.025 0.7 0.034 0.024 0.2 3.1 0.38
AA 0.003 0.022 0.9 0.014 0.021 0.5 0.003 0.021 0.9 0.42 0.94
XA 0.049 0.023 0.03 0.024 0.023 0.3 0.047 0.022 0.03 7.3 0.06
HK -0.002 0.242 0.9 -0.009 0.024 0.7 0.026 0.023 0.3 1.8 0.6
HAA 0.032 0.023 0.2 0.013 0.023 0.6 0.043 0.022 0.05 4.7 0.2
PIC 0.031 0.022 0.2 0.005 0.021 0.2 0.005 0.021 0.8 2.0 0.6
QA -0.007 0.024 0.8 -0.050 0.024 0.04 0.034 0.023 0.1 9.0 0.03
KTR -0.084 0.024 0.001 -0.077 0.024 0.001 -0.032 0.023 0.16 17.7 < 0.001*
Neopt -0.074 0.023 0.001 -0.056 0.022 0.01 -0.007 0.022 0.8 14.6 0.002*
KA/QA 0.022 0.021 0.3 0.028 0.021 0.2 -0.003 0.021 0.9 2.8 0.43
Association between KTR and three cognitive tests, with covariates
β SE p β SE p β SE p X2 p
Age
71 -0.024 0.050 0.6 0.072 0.049 0.1 -0.040 0.048 0.4 4.3 0.2
72 -0.050 0.050 0.3 0.072 0.049 0.1 -0.062 0.048 0.2 6.8 0.1
Female 0.408 0.044 <0.001 0.072 0.043 0.1 0.085 0.042 0.05 85.6 < 0.001
GFR -0.061 0.024 0.01 -0.067 0.024 0.005 -0.033 0.023 0.2 11.5 0.01
Edu 0.150 0.022 <0.001 0.340 0.022 < 0.001 0.402 0.021 <0.001 486.7 < 0.001
Smoke -0.021 0.050 0.7 -0.016 0.049 0.8 -0.061 0.048 0.2 1.8 0.6
Dia -0.103 0.086 0.2 -0.206 0.084 0.01 -0.090 0.082 0.3 6.8 0.08
BMI -0.001 0.006 0.8 -0.005 0.005 0.4 0.001 0.005 0.8 0.92 0.8
HT -0.045 0.046 0.3 -0.014 0.045 0.8 -0.049 0.044 0.3 1.5 0.7
MI -0.123 0.069 0.07 -0.051 0.067 0.4 -0.022 0.066 0.7 3.4 0.3
Stroke -0.246 0.098 0.01 -0.208 0.097 0.03 -0.091 0.095 0.3 8.7 0.03
PLP -0.003 0.022 0.9 0.032 0.021 0.1 0.069 0.021 0.001 13.1 0.005
KTR -0.084 0.024 0.001 -0.077 0.024 0.001 -0.032 0.023 0.16 17.7 < 0.001*
a Zellner’s seemingly unrelated regression, estimated for each metabolite with age, BMI, dia, edu, GFR, MI, sex, smoking, hypertension, MI, stroke and PLP as
covariates.
b The association between KOLT and KYN was non-linear. A second degree orthogonal polynomial gave a good fit.
c The significance threshold for 12 tests is 0.0042, according to the Bonferroni method, indicated by *.
d Test of the joint significance of the association between each metabolite and three cognitive outcomes. AA, anthranilic acid; BMI, body mass index; COWAT,
Controlled Oral Word Association Test; Dia, diabetes; DST, Digit Symbol Test; Edu, education; GFR, glomerular filtration rate; HAA, 3-hydroxyanthranilic acid; HK, 3-
hydroxykynurenine; HT, hypertension; KA, kynurenic acid; KA/QA, kynurenic acid-quinolinic acid ratio; KOLT, Kendrick Object Learning Test; KYN, kynurenine;
KYN2, 2nd degree orthogonal polynomial of KYN; KTR, kynurenine-tryptophan ratio; MI, previous myocardial infarction; Neopt, neopterin; p, p-value; PIC, picolinic
acid; PLP, pyridoxal 5′phosphate; QA, quinolinic acid; SE, standard error; Smoker, current smoking; Stroke, prior stroke; TRP, tryptophan; X2, chi-squared; XA,
xanthurenic acid; β, standardized regression coefficient.
S.-E.H. Solvang et al. Brain, Behavior, and Immunity 75 (2019) 155–162
159
supplementation for age-related memory decline has shown some en-
couraging trends (Deijen et al., 1992). However, given the involvement
of PLP in a wide range of biological processes, it remains to be de-
termined if PLP plays an active role in cognitive performance.
Our rationale for using the KTR was that it provides a better mea-
sure of IDO activity than the individual metabolites, particularly when
KTR correlates with inflammatory markers, such as neopterin
(Schrocksnadel et al., 2006). The rate-limiting enzymes in kynurenine
and neopterin biosynthesis, IDO and GTP-CH respectively, are both
induced by IFN-γ. The absence of IFN-γ is associated with improve-
ments in neurogenesis, synaptic plasticity, and performance in hippo-
campus-dependent tasks in mice (Monteiro et al., 2016). Experimental
studies have implicated IDO in inflammation-associated cognitive dys-
function (Chen and Guillemin, 2009; Comim et al., 2017; Heisler and
O'Connor, 2015; Yu et al., 2015).
Experimental studies support a neuroexcitatory role of QA in the
brain, and a neuroprotective role of KA. The hippocampus has been
reported to be particularly susceptible to the neurotoxic effects of QA
(Schwarcz and Kohler, 1983). KA, on the other hand, is considered
neuroprotective (Leib et al., 1996). We did not find evidence to support
that the ratio between these metabolites (KA/QA) in peripheral blood
was related to cognitive function. However, QA and KA cross the BBB
poorly (Fukui et al., 1991), and therefore measurement in the cere-
brospinal fluid will be needed to settle this issue.
An important question in studies such as ours is to what extent, if
any, peripheral inflammation relates to neuroinflammation. Blood-
borne cytokines can enter the brain by transport systems at the BBB
(Varatharaj and Galea, 2017) and immune cells enter the brain under
physiological conditions, though at a much lower rate than in other
organs (Takeshita and Ransohoff, 2012). TRP and KYN are themselves
transported to the brain and are precursors of both brain serotonin
(Young and Leyton, 2002) and kynurenines (Chen and Guillemin,
2009). In microglia, KYN is a precursor for QA, which could activate the
N-methyl-D-aspartate receptor (NMDAR) (Ganong and Cotman, 1986).
Thus, high plasma KTR may be related to cognitive function as a marker
of inflammation, serotonin depletion and NMDAR activation in the
brain, but this must be investigated in future studies.
Strengths of this study include a large sample size of 2174 persons, a
Table 3
Evaluating potential confounders. Association with exposure a.
Depressive symptoms b Anti-depressants b NSAIDs b C-reactive protein c
OR p OR p OR p β p
TRP 1.01 0.9 0.91 0.4 0.65 < 0.001 -0.02 0.3
KYN 0.94 0.5 1.16 0.3 0.74 0.003 0.19 < 0.001
KA 0.88 0.2 0.89 0.4 0.96 0.7 0.04 0.2
AA 0.89 0.2 0.98 0.9 1.2 0.1 0.06 0.003
XA 0.93 0.4 0.80 0.1 0.93 0.4 -0.04 0.05
HK 1.10 0.3 1.06 0.7 1.00 0.9 0.17 < 0.001
HAA 0.97 0.7 1.11 0.4 0.93 0.5 0.15 < 0.001
PIC 0.98 0.8 0.87 0.2 1.02 0.9 -0.02 0.3
QA 0.98 0.8 1.07 0.6 1.02 0.82 0.24 < 0.001
KTR 0.94 0.5 1.27 0.1 1.29 0.01 1.21 < 0.001
Neopt 1.09 0.3 1.20 0.1 1.03 0.74 0.18 < 0.001
KA/QA 0.94 0.4 0.88 0.3 0.95 0.6 -0.15 < 0.001
Note. 252/2869 had depressive symptoms, 141/3319 used anti-depressants, and 196/3319 used NSAIDs.
a All models adjusted for age, body mass index, current smoking, diabetes, educational level, glomerular filtration rate, hypertension, previous myocardial
infarction, prior stroke, pyridoxal 5′ phosphate and sex.
b Logistic regression.
c Linear regression. AA, anthranilic acid; HAA, hydroxyanthranilic acid; HK, hydroxykynurenine; KA, kynurenic acid; KA/QA, kynurenic acid-quinonilic acid ratio;
KTR, kynurenine-tryptophan ratio; KYN, kynurenine; Neopt, neopterin; OR, odds ratio; p, p-value; PIC, picolinic acid; QA, quinonilic acid; TRP, tryptophan; X2, chi-
squared; XA, xanthurenic acid; β, standardized regression coefficient.
Table 4
Cognitive performance and individual metabolites. Adjusted models (N= 2174).a
KOLT COWAT DST Wald testb
Memory Language Executive function
Model 1: Unadjusted model
β SE p β SE p β SE p X2 P
KTR -0.084 0.024 0.001 -0.077 0.024 0.001 -0.032 0.023 0.2 17.7 <0.001
Neopt -0.074 0.023 0.001 -0.056 0.022 0.01 -0.007 0.022 0.8 14.6 0.002
Model 2: Adjustment for C-reactive protein
KTR -0.078 0.025 0.002 -0.081 0.025 0.001 -0.040 0.024 0.1 16.1 0.001
Neopt -0.071 0.024 0.003 -0.052 0.023 0.02 -0.011 0.022 0.6 11.7 0.008
Model 3: Adjustment for non-steroidal anti-inflammatory drugs
KTR -0.082 0.024 0.001 -0.079 0.024 0.001 -0.032 0.023 0.2 17.8 <0.001
Neopt -0.074 0.022 0.001 -0.055 0.022 0.01 -0.007 0.022 0.7 14.5 0.002
Note. 196 out of 3319 participants used non-steroidal anti-inflammatory drugs.
a Zellner’s seemingly unrelated regression, estimated for each metabolite with age, sex, body mass index, educational level, glomerular filtration rate, current
smoking, diabetes, hypertension, previous myocardial infarction, prior stroke, pyridoxal 5′ phosphate as covariates and either CRP (Model 2) or NSAIDs (Model 3).
b Test of the joint significance of association between each metabolite and all three cognitive outcomes. Neopt, neopterin; KTR, kynurenine-tryptophan ratio; p, p-
value; SE, standard error; X2, chi-squared; β, standardized regression coefficient.
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relatively high response rate among the participants, and similar age of
the participants (70–72 years), which limits the impact of age itself on
metabolites and cognition. The main limitations are the constraints of
cross-sectional studies. This involves difficulties in ascertaining the di-
rection of associations between predictors and outcomes and the po-
tential for unmeasured confounders. Cognitive domains are not mu-
tually exclusive, which can make interpretation challenging (Malek-
Ahmadi et al., 2011). Further, non-fasting blood samples is a limitation,
and measurements of the kynurenines in the cerebrospinal fluid would
have been informative. Longitudinal studies are needed to further de-
lineate these associations.
In summary, we found that KTR and neopterin, biomarkers of cel-
lular immune activation, were associated with a lower cognitive func-
tion in the domains of memory and language in a sample of community-
dwelling older adults. The findings add support for a role of the innate
immune system in cognitive function.
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Supplementary Figure 1. Ceiling effects in MMSE and Block Design 
 
The 12-point MMSE displayed considerable ceiling effects. 90.3 % scored ≥ 11 points; of these, 26.5% 
scored 11 and 63.8% scored 12 points. 87.7% of these participants also scored 16 out of 16 points on 
Block Design (97.7% scored 12 points or more). The ceiling effects were increased amongst 
participants with higher education. 2152 participants completed the Mini-Mental Status Examination, 




Supplementary Figure 2. Distributions of KOLT, COWAT and DST 
 
First row = histograms, second row = bivariate distributions with regression lines. COWAT, Controlled 
Oral Word Association Test; DST, Digit Symbol Test; KOLT, Kendrick Object Learning Test; p, p-
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The essential amino acid tryptophan (Trp) is degraded through 
the kynurenine pathway (Figure 1), giving rise to metabolites 
referred to as kynurenines.1 The kynurenine pathway is most 
highly expressed not only in liver and monocytes2 but also in 
muscle, brain, and intestine.3 The kynurenines and the rate-
limiting enzyme indoleamine 2,3-dioxygenase (IDO) of the 
kynurenine pathway have been implicated in experimental 
cognitive dysfunction in mice,4-7 and kynurenines are lower in 
Alzheimer’s disease (AD) compared with healthy controls.8
Tryptophan 2,3-dioxygenase (TDO) and IDO generate 
kynurenine (Kyn) from Trp,9 which gives rise to downstream 
metabolites that have shown neuroprotective (kynurenic acid 
[KA])10 and neurotoxic properties (quinolinic acid [QA]).11 
Both KA and QA act as antagonist and agonist, respectively, 
at the N-methyl-d-aspartate receptor (NMDAR), suggest-
ing a potential role of kynurenines in relation to signal trans-
duction pathways related to cognitive dysfunction.12 The key 
enzymes IDO and kynurenine 3-monooxygenase (KMO) are 
induced by pro-inflammatory cytokines. KMO converts Kyn 
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to 3-hydroxykynurenine (HK).13 Interferon gamma (IFN-γ) 
is the most potent activator.2 Higher circulating levels of 
kynurenine metabolites are associated with depression14 and 
elevated postmortem brain levels of kynurenines, and rele-
vant enzymes have been observed in patients with psychotic 
and mood disorders.15-19 Cerebrospinal fluid (CSF) levels of 
KA were not significantly altered in patients with dementia 
with Lewy bodies (DLB) compared with controls.20 The 
kynurenine-to-tryptophan ratio (KTR) and neopterin, which 
are biomarkers of cellular immune activation, have been 
associated with reduced cognitive performance in commu-
nity-dwelling older adults.21
We aimed to assess whether the levels of circulating kynure-
nines at baseline predicted cognitive prognosis and neuropsy-




The Dementia Study of Western Norway (DemVest) is a mul-
ticenter longitudinal cohort study with annual follow-up until 
death. The study recruited 155 participants from specialist 
clinics of neurology and old-age psychiatry situated in the 
Norwegian counties Hordaland and Rogaland with available 
blood samples in a biobank. Participant recruitment during 
2005 to 2007 relied on fulfillment of the inclusion criteria: 
patients diagnosed with mild dementia for the first time and a 
minimal Mini-Mental State Examination (MMSE) score of 
20.22 Thereafter, selective recruitment of patients with either 
DLB or Parkinson disease with dementia (PDD) was under-
taken. Thus, the latter 2 patient groups are overrepresented in 
the study. Due to similar pathologies, DLB and PDD were 
classified together as LBD.
Independently, 2 physicians experienced in the diagnostic 
workup of dementia made a clinical diagnosis using the 
NINCDS-ADRDA criteria for AD (National Institute of 
Neurological and Communicative Disorders and Stroke and 
Alzheimer’s Disease and Related Disorders Association)23 and 
the revised consensus criteria for DLB (2005).24 A detailed study 
protocol has been published.22 Briefly, a physician interviewed 
the patient together with a caregiver who provided complemen-
tary information. Medical history was also obtained from elec-
tronic records and a clinical neurological examination was 
performed. In addition to a global cognitive assessment of cogni-
tion by the MMSE, and dementia severity using Clinical 
Dementia Rating, patients were assessed with a standardized 
neuropsychological test battery. In situations with diagnostic 
uncertainty, physicians discussed each case until consensus. In 
addition, after 5 years, 3 specialists in geriatrics and psychiatry 
revised the diagnoses in consensus meetings. All patients were 
followed longitudinally with annual assessments with MMSE 
and the Neuropsychiatric Inventory (NPI), mostly until death. 
Due to the progressive nature of dementia, most patients fol-
lowed over time will reach a point where they score 0 on the 
MMSE on each consecutive follow-up. This is called the floor 
effect. At this point, the MMSE can no longer measure further 
disease progression, and for a statistical model, it will look as if 
disease progression has stopped. Furthermore, variance will be 
reduced at follow-ups with many 0 scores. This will result in the 
introduction of a range of statistical biases, which are not easily 
compensated for, especially if a substantial proportion of patients 
reach a floor or ceiling effect.25 Therefore, a decision was made 
to censor the study on biomarkers after the fifth follow-up.
Postmortem studies from the full DemVest study (56 
autopsies) found that the concordance rate for a clinical diag-
nosis compared with a pathological diagnosis was 83% for AD 
and 80% for LBD.26
Some data during follow-up were missing. Most were 
observed in an intermittent pattern, meaning that the patient 
missed one appointment and later returned to the study. The 
proportion of missing measurements that was not due to death 
was small. The MMSE and NPI were assessed at the same visit 
and thus had largely corresponding missing measurements. 
Accordingly, missing measurements for the MMSE are listed. 
For the MMSE, there were no missing measurements at base-
line, 6 missing measurements at the first follow-up, 11 at the 
second follow-up, 9 at the third follow-up, 6 at the fourth 
Figure 1. The kynurenine pathway. TDO and IDO convert tryptophan to 
kynurenine (Kyn). HK (3-hydroxykynurenine) is converted to 
3-hydroxyanthranilic acid (HAA) by kynureninase (KYNU), and 
subsequently to quinolinic acid (QA), catalyzed by quinolinate 
phosphoribosyl transferase. QA is converted to nicotinamide adenosine 
dinucleotide (NAD+), the final product of the pathway. Anthranilic acid 
(AA) is produced from Kyn by KYNU. Kynurenine aminotransferases 
(KATs) generate KA from Kyn and xanthurenic acid (XA) from HK. 
Picolinic acid (PIC) is produced by spontaneous conversion of HAA. Both 
KYNU and KATs have pyridoxal 5′-phosphate (PLP) as a cofactor.9 IDO 
indicates indoleamine 2,3-dioxygenase; TDO, tryptophan 2, 
3-dioxygenase; KMO, kynurenine 3-monooxygenase; KATs, kynurenine 
aminotransferases; 3-HAO, 3-hydroxyanthranilic acid 3, 4-dioxygenase; 
Spont., spontaneous; NAD+, nicotine adenine dinucleotide; HK, 
3-hydroxykynurenine; HAA, 3-hydroxyanthranilic acid.
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follow-up, and 8 at the fifth follow-up. During the study 
period, several patients died prior to their planned follow-up. 
At the second follow-up, 15 patients had died, 34 at the third, 
55 at the fourth, and 78 at the fifth follow-up.
The Mini-Mental State Examination
The MMSE has maximum score of 30 and a minimum of 0 and 
consists of a variety of questions, grouped into 7 categories rep-
resenting different cognitive domains. The categories are orien-
tation to time, orientation to place, registration of 3 words, 
attention and calculation, recall of 3 words, language, and visual 
construction.27 A decline of 2 to 4 points is considered a reliable 
change,28 and about 3 points is also the expected annual decline.29
The Neuropsychiatric Inventory
The NPI evaluates 12 neuropsychiatric symptoms common in 
dementia: delusions, hallucinations, agitation, apathy, dyspho-
ria, anxiety, irritability, euphoria, disinhibition, motor distur-
bances, and sleep- and appetite disturbances. A caregiver 
familiar with the patient rates the severity and frequency of 
each neuropsychiatric symptom using a standardized question-
naire. A combined score for each symptom is calculated by 
multiplying the frequency by severity. The total score is deter-
mined by adding all the domain scores together.30 We used the 
NPI total score to limit the number of outcomes.
Measurement of metabolic biomarkers
Baseline levels of Trp, anthranilic acid (AA), 3-hydroxyan-
thranilic acid, HK, KA, Kyn, picolinic acid, QA, xanthurenic 
acid (XA), pyridoxal 5′-phosphate (PLP), and neopterin were 
measured using liquid chromatography-tandem mass spec-
trometry in serum samples, collected between 2005 and 2009, 
and stored at −80°C until analysis in 2018. The ratio between 
Trp and Kyn (KTR) was defined as Kyn (µM)/Trp (µM)*100 
and the kynurenic acid-to-kynurenine ratio (KKR) was esti-
mated. The limit of detection for neopterin and the kynure-
nines ranged from 0.5 to 7 nmol/L, whereas the limit of 
detection for Trp was 0.4 µmol/L. Within-day and between-
day coefficients of variation were 5.7% to 16.9% and 3.0% to 
9.5%, respectively. The biochemical analyses were performed at 
the laboratory of Bevital AS (Bergen, Norway; http://bevital.
no). We did not detect any significant correlations between 
metabolite levels and storage time using Spearman rank order 
correlations (data not shown).
Statistics
Univariate differences between AD and LBD were assessed 
using t tests, Pearson χ2, and Mann-Whitney U tests for nor-
mal, categorical, and skewed variables, respectively. Metabolite 
concentrations were transformed to approximate normality 
using Tukey’s ladder of powers.31 A constant of one was added 
prior to logarithmic transformation for all metabolites with a 
minimum concentration below 1 to avoid an uneven spread of 
the data after logarithmic transformations. Associations 
between cognitive deterioration and neuropsychiatric symp-
toms over 5 years and baseline metabolite levels were examined 
in a multiprocess model or joint model. Of note, although 
patients underwent 5 annual follow-up examinations, there 
were occasional delays, and some patients were followed for 
6 years. The MMSE test scores were transformed by the square 
root of errors, √(30-MMSE), thereby higher values indicate 
poorer performance. The MMSE raw scores were right skewed 
toward higher scores, which is problematic in statistics, as 
transformations typically work best to obtain normality with 
left-skewed data. Thus, the reciprocal of MMSE (30 − MMSE) 
was calculated to obtain a right-skewed distribution of the 
number of errors committed by patients on the MMSE (an 
MMSE score of 24 is 30 − 24 = 6 errors). After this, the square 
root transformation of the MMSE errors resulted in an approx-
imately normal distribution as assessed by quantile-quantile 
plots and histograms.32 However, 37 measurements of the 
transformed MMSE test scores reached a ceiling effect. Thus, 
right censoring was implemented using a linear mixed-effects 
Tobit model with random intercepts and slopes.
The NPI total score was best fitted using a negative bino-
mial random intercept model, according to the Bayesian 
information criterion. Random slopes could not be fitted, 
likely due to considerable individual deviation from a linear 
slope. The MMSE and NPI total models were linked by cor-
related random effects, implemented using a generalized 
structural equation model framework (Stata 15 package 
“gsem”). Each metabolite measured at baseline was entered in 
a separate multiprocess model, with years in study (time), age, 
age*time interaction, sex, AD vs LBD, AD vs LBD*time 
interaction, current smoking, glomerular filtration rate, and 
PLP as independent variables in the MMSE model. The 
independent variables were the same in the NPI total model, 
without a nonsignificant age*time interaction. Nonlinearity 
was checked using orthogonal polynomials of the trans-
formed metabolite levels.
Post hoc, we compared the multiprocess models stratified by 
diagnosis. We further assessed the association between metab-
olite concentrations and the presence of individual NPI items 
(domain score ⩾1) using a logistic random intercept model 
with time, age, sex, AD vs LBD, AD vs LBD*time interaction, 
current smoking, glomerular filtration rate, and PLP as inde-
pendent variables. Finally, all study findings were adjusted for 
multiple comparisons, using the tail area–based false discovery 
rate (FDR) due to dependency, and adjusted P values are 
reported (Q values or Q). This was done separately for post hoc 
tests (R package: fdrtool).33,34 The statistical analyses, besides 
FDR correction, were conducted in Stata (version 15; 
StataCorp, College Station, TX, USA).
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Ethics
The Regional Committee for Medical and Health Research 
Ethics approved the study protocol and a notification of change 
relating to biomarker analyses (REC number: 2010/633). All 
participants provided signed informed consent at baseline after 
a detailed explanation of the procedures.
Results
Study participants
The study included 155 patients (56% women) with 
dementia (90 AD, 65 LBD). The baseline mean MMSE 
score was 23.7 and mean educational level was 9.7 years. A 
total of 20% of the patients were current smokers at base-
line (Table 1).
Kynurenines and cognitive performance
Kynurenine measured at baseline had a significant nonlinear, 
quadratic, relationship with the average MMSE score over the 
5 follow-up examinations (Table 2, Figure 2), but not with the 
rate of change. Using orthogonal polynomials, the first polyno-
mial of kynurenine, representing a linear relationship, was not 
significant (estimate [Est.] −0.023, Q = 0.840), whereas the sec-
ond, representing a nonlinear relationship, was significant (Est. 
0.10, Q = 0.035).
Table 1. Participant demographics of the Dementia Study of Western Norway and serum metabolite concentrations at baseline.
CLINICAL CHARACTERISTICS DEMENTIA (N = 155) AD (N = 90) LBD (N = 65) P VALUE
Age, y, mean (SD) 75.1 (7.31) 75.1 (7.8) 75.1 (6.3) .694a
Education, y, mean (SD) 9.7 (3.0) 9.7 (3.1) 9.6 (2.8) .738a
Female, % 56.1 67.8 40.0 .001b*
Lewy body disease, % 42.3  
Current smokers, % 20.0 23.3 15.4 .222b
MMSE, score, mean (SD) 23.7 (2.8) 23.6 (2.5) 23.8 (3.1) .597a
GFRc, mean (SD) 79.2 (20.4) 79.2 (22.4) 80.7 (25.4) .459a
METABOLITES
Trpd,e 66.2 (22.4) 66.0 (22.8) 66.6 (15.5) .547f
Kynd,e 1.74 (0.67) 1.74 (0.58) 1.74 (0.73) .582f
HKe,g 50.0 (33.7) 48.0 (28.8) 54.4 (34.3) .033f*
KAe,g 51.1 (24.4) 51.5 (21.7) 50.2 (25.8) .772f
XAe,g 12.3 (9.0) 12.5 (8.9) 12.3 (9.9) .558f
AAe,g 21.7 (10.7) 20.1 (11.5) 22.5 (8.6) .539f
HAAe,g 36.1 (16.5) 35.2 (16.2) 39.2 (16.3) .360f
PICe,g 35.9 (22.4) 33.0 (18.0) 38.1 (26.5) .143f
QAe,g 474 (312) 465 (312) 481 (309) .736f
KTRe 2.59 (1.06) 2.49 (1.02) 2.69 (0.96) .244f
KKRe 7.97 (0.43) 8.00 (0.40) 7.95 (0.41) .357f
Neopte,g 19.7 (14.0) 18.7 (11.3) 20.6 (15.3) .276f
PLPe,g 31.6 (33.9) 34.0 (33.7) 29.6 (24.9) .021f*
Abbreviations: AA, anthranilic acid; AD, Alzheimer’s disease; GFR, glomerular filtration rate; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; KA, kynurenic 
acid; KTR, kynurenine-to-tryptophan ratio; Kyn, kynurenine; LBD, Lewy body dementia; MMSE, Mini-Mental State Examination; Neopt, neopterin; PIC, picolinic acid; PLP, 
pyridoxal 5´-phosphate; Trp, tryptophan; QA, quinolinic acid; XA, xanthurenic acid.
aStudent t test.
bPearson χ2 test.
cMetabolite levels in median and interquartile range.
dMicromoles per liter.
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Kynurenines and neuropsychiatric symptoms
The kynurenic acid-to-kynurenine ratio was positively associ-
ated with the rate of change per year in neuropsychiatric symp-
toms, specifically with more neuropsychiatric symptoms over 
time (Q = 0.045; see Figure 3). There was a trend for KA and 
XA to also be positively associated with more neuropsychiatric 
symptoms over time, but these findings were not significant 
after adjustment for multiple comparisons (Table 2).
Post hoc analyses
Differences in prognostic associations of kynurenines between AD 
and LBD. The associations between the kynurenines, cogni-
tive prognosis, and neuropsychiatric symptoms over 5 years did 
not differ between AD and LBD after corrections for multiple 
comparisons (no significant interaction by clinical diagnosis 
[AD versus LBD]; Supplementary Table 1, and Supplemen-
tary Figure 1).
Individual neuropsychiatric symptoms. The kynurenic acid-to-
kynurenine ratio was significantly associated with an increasing 
probability of hallucinations over time (odds ratios in Figure 4 
indicate increased odds per year), whereas KA was significantly 
associated with more hallucinations, on average, over 5 years 
(Q < 0.001) with no change over time. There were several other 
observed trends. Of note, KA, KKR, and XA displayed trends 
for increasing agitation over time. Kyn, AA, QA, neopterin, 
and KTR showed trends for association with reduced average 
test scores on the item for irritability, whereas Trp, Kyn, HK, 
and neopterin displayed trends for association with higher 
average probabilities of experiencing apathy (Figure 4).
Discussion
In this study, Kyn had a nonlinear relationship with the partici-
pants’ average MMSE test performance over 5 years. This rela-
tionship suggests that both low and high levels of Kyn are 
associated with poorer MMSE test performance, as compared 
Table 2. Associations between serum kynurenines and neopterin at baseline and 5-year prognosis in dementia.a
COGNITIVE PERFORMANCE (MMSE) NEUROPSYCHIATRIC SYMPTOMS (NPI TOTAL SCORE)
 EST. SE P VALUE Q EST. SE P VALUE Q
Trp 0.059 0.044 .185 Trp 0.010 0.055 .852  
Kyn −0.023 0.052 .656 Kyn −0.036 0.065 .569  
Kyn2 0.102 0.030 .006* .046*  
AA −0.080 0.048 .096 AA −0.097 0.058 .099  
KA 0.072 0.057 .209 KA −0.049 0.087 .575  
 KA*T 0.051 0.022 .021* .080
HK −0.099 0.060 .099 HK −0.005 0.077 .950  
XA 0.017 0.050 .728 XA −0.101 0.077 .190  
 XA*T 0.051 0.021 .017 .075
HAA −0.004 0.048 .932 HAA 0.027 0.058 .636  
QA −0.014 0.052 .795 QA −0.087 0.063 .170  
PIC 0.011 0.045 .808 PIC 0.022 0.057 .701  
Neopt 0.023 0.050 .647 Neopt −0.086 0.060 .149  
KTR 0.023 0.051 .648 KTR −0.074 0.064 .247  
KKR 0.092 0.046 .046 .133 KKR −0.050 0.074 .501  
 KKR*T 0.063 0.021 .003 .045*
Abbreviations: AA, anthranilic acid; Est., estimate; GFR, glomerular filtration rate; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; KA, kynurenic acid; KKR, 
kynurenic acid-to-kynurenine ratio; KTR, kynurenine-to-tryptophan ratio; Kyn, kynurenine; Kyn2, second degree orthogonal polynomial of Kyn; MMSE, Mini-Mental State 
Examination; Neopt, neopterin; NPI, Neuropsychiatric Inventory; PIC, picolinic acid; PLP, pyridoxal 5´-phosphate; SE, standard error; Trp, tryptophan; Q, Q value; QA, 
quinolinic acid; XA, xanthurenic acid.
aGeneralized structural equation model linking 2 mixed models by their random effects: Model 1: Tobit mixed-effects model with MMSE as the outcome, measured at 
baseline and for 5 consecutive years. Model includes random intercepts and slopes. MMSE transformed to √(30 − MMSE). Model 2: Negative binomial mixed-effects 
model with NPI total (sum of items 1 through 10) measured at baseline and for 5 consecutive years. Model includes random intercepts. Link: Random intercepts and 
slopes of MMSE correlated with random intercepts of NPI total. Covariates: Time, age (also *time for MMSE), sex, Lewy body dementia vs Alzheimer disease (also 
*time), current smoking, GFR, and PLP as independent variables.
*P < .05 or Q < 0.05.
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with values around the mean. Kynurenine was not associated 
with the rate of MMSE decline over time. A higher KKR was 
significantly associated with increasing neuropsychiatric symp-
toms over time. In post hoc analyses, we found that KKR and 
KA were significantly associated with more hallucinations. The 
associations between the kynurenines, cognitive prognosis, and 
neuropsychiatric symptoms over 5 years did not differ between 
patients with AD or LBD. However, several trends were 
observed, which should be investigated in a study with statisti-
cal power for subgroup analyses.
Kynurenine showed a nonlinear association with average 
MMSE score over 5 years (Figure 2), but not with the rate of 
change. Previously, we observed a similar nonlinear trend 
between Kyn and cognitive function in a cohort of community-
dwelling older adults.21 This may suggest that a homeostatic 
level of Kyn around the mean value can be beneficial for cogni-
tive function. One might speculate that the lack of association 
between kynurenines and the rate of cognitive decline suggests 
that circulating kynurenines are not related to strong drivers of 
cognitive deterioration, such as synaptic loss35 and tau pathol-
ogy.36 Availability of precursors of neuroactive kynurenines 
which are linked to both nicotinamide adenosine dinucleotide 
(NAD+) metabolism9 and low-grade inflammation,13 could 
lead to cognitive differences that are stable throughout the 
disease course. Circulating Kyn, which crosses the blood- 
brain-barrier (BBB), may affect kynurenines in the brain, as 
both TDO and IDO converting Trp to Kyn have low activity 
in the brain.9 Furthermore, Kyn is induced by pro-inflamma-
tory cytokines, but notably also gives rise to metabolites that 
suppress inflammation, indicating a complex relationship.37 
There is ample evidence that IDO activation has a negative 
impact on cognitive function in rodent models4-7 and can exac-
erbate AD pathology in amyloid knock-in mice.5 However, it 
is less clear how IDO activity outside the brain relates to cog-
nitive function. Peripheral interferon alpha may increase both 
blood and CSF levels of Kyn.38 Kynurenine could be a marker 
of IFN-γ activity, but neopterin and KTR, which are more 
strongly related to IFN-γ induction,39,40 were not associated 
with cognitive function in older humans.21 Whereas high Kyn 
levels may signify inflammation,13 low levels may limit the 
availability of a key precursor of neuroactive kynurenines and 
perhaps NAD+.9 Deficiency of kynurenines may explain poor 
outcomes with low Kyn levels, by decreasing levels of NAD+ 
leading to neuronal degeneration in dementia. Reduced avail-
ability of NAD+ may impair the activity of the NAD+-
dependent enzymes, such as the sirtuins, resulting in 
accumulation of amyloid-beta plaques and tau tangles.41
A higher KKR was significantly associated with more neu-
ropsychiatric symptoms over time. A similar association was 
found in post hoc analysis, suggesting that KKR was related to 
hallucinations with a similar trend for delusions and disinhibi-
tion, indicative of psychotic symptoms. Kynurenic acid was 
significantly associated with hallucinations independent of 
time in post hoc analysis, with a similar trend for agitation. 
The NMDAR antagonism, a function of KA, is a known trig-
ger of psychosis,42 and KA is increased in the brain19 and CSF 
of patients with schizophrenia,43 making this finding intrigu-
ing. Increased KA levels, indicating higher kynurenine ami-
notransferase (KAT) activity, may produce symptoms of 
Figure 2. Nonlinear association between MMSE and kynurenine. Low 
levels of kynurenine are associated with more errors on the MMSE on 
average (intercept). At mean kynurenine levels, there is no association 
with MMSE, whereas high or low serum concentrations are associated 
with more average MMSE errors. The model was estimated as a 
multiprocess model together with a model for the NPI total score (see 
statistics). Of note, a constant of 1 was added to kynurenine prior to 
logarithmic transformation to avoid an uneven spread below and above a 
kynurenine level of 1, shifting the log (mean) from 0.55 to 1.02. MMSE 
indicates Mini-Mental State Examination; NPI, Neuropsychiatric 
Inventory.
Figure 3. Kynurenic acid-to-kynurenine ratio and neuropsychiatric 
symptoms. The graph shows how a change in 1 standard deviation of the 
transformed and standardized levels of KKR, the reciprocal of 1/√(KKR) 
is associated with an increase in neuropsychiatric symptoms over time, 
using a negative binomial random intercept model, adjusted for age, sex, 
current smoking, glomerular filtration rate, and PLP in the model for 
MMSE. KKR indicates kynurenic acid-to-kynurenine ratio; MMSE, 
Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.
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schizophrenia in experimental animals.44 In addition, mice 
with genomic deletion of the KAT II enzyme show improved 
cognitive function.45 Furthermore, KA may lead to decreased 
levels of the neurotransmitters glutamate,46 dopamine,47 and 
acetylcholine,48 and KA has been linked to elevated dopamin-
ergic activity in the brain.49 KKR might reflect the activity of 
peripheral KATs in the periphery. Notably, KATs also generate 
XA, which was associated at trend toward more neuropsychi-
atric symptoms over time, specifically, agitation in post hoc 
analyses. However, contrary to Kyn, KA does not cross the 
BBB, but is formed in the brain from Kyn catalyzed by KATs.50 
Accordingly, follow-up studies measuring CSF kynurenines 
would be highly informative. In addition, KA is an agonist for 
the aryl hydrocarbon receptor51,52 and is an antagonist of α7 
nicotinic acetylcholine receptors (α7nAChR), both implicated 
in schizophrenia.53,54
There were several nonsignificant associations in post hoc 
analyses indicating that in particular AA and QA, but also 
KTR, Kyn, and neopterin, could be associated with less irri-
tability and motor disturbances. It is interesting that 
increased concentrations of many of these metabolites may 
indicate metabolic flux away from KA. Reduced activity of 
KMO, linked to higher KA,55 has been shown in 
schizophrenia.56
Our study suggests that increased circulating KA and KKR, 
potentially related to KAT activity, could be biomarkers of an 
increased risk of neuropsychiatric symptoms in dementia. 
Furthermore, several direct and indirect effects of kynurenines 
on neurotransmitter receptors51-54 suggest the possibility of a 
potential role in the pathogenesis of such symptoms. There are 
several important regulators of the kynurenine pathway in the 
periphery, such as IFN-γ40 and interleukin 1β (IL-1β).57 
Furthermore, IL-1β can affect the activity of KAT.57 Thus, 
both clinical and experimental studies are needed to confirm 
and elaborate on our findings.
Strengths of the study include its longitudinal design with 
annual follow-up examinations until death, a low dropout 
rate among the participants and centralized laboratory analy-
ses of all metabolites. The main limitations are a relatively 
small sample size, use of nonfasting blood samples, lack of 
longitudinal measurements of kynurenines, and KKR might 
not accurately reflect KAT activity. Furthermore, we could 
Figure 4. Post hoc: neuropsychiatric symptoms and metabolites. The bubble diagram shows associations between individual neuropsychiatric symptoms 
over 5  years and metabolites assessed by logistic random intercept models. The KKR was significantly associated with an increasing probability of 
hallucinations over time, whereas KA was significantly associated with more hallucinations, on average, over 5  years. The analyses were adjusted for 
using the Benjamini-Hockberg procedure with a false discovery rate of 0.05, and Q values, representing adjusted P values, were estimated. The bubble 
sizes are proportional to −log10 P values. Odds ratios (ORs) are depicted inside bubbles with thin dark borders representing significant P values and thick 
dark borders representing significant Q values. Light blue coloring represents an OR of <1, whereas pink represents an OR >1. Odds ratios are stratified 
by color transparency as 0% (OR: 0.60-0.69/1.75-2.00), 20% (OR: 0.70-0.79/1.50-1.74), 40% (OR: 0.80-0.89/1.25-1.49), 60% (OR: 0.90-0.99, 1.00-1.24). 
AA indicates anthranilic acid; HAA, 3-hydroxyanthranilic acid; HK, 3-hydroxykynurenine; KA, kynurenic acid; KA*T, kynurenic acid interaction with time; 
KKR, kynurenic acid-to-kynurenine ratio; KKR*T, kynurenic acid-to-kynurenine ratio interaction with time; KTR, kynurenine-to-tryptophan ratio; Kyn, 
kynurenine; Neopt, neopterin; OR, odds ratio; PIC, picolinic acid; Trp, tryptophan; QA, quinolinic acid; XA, xanthurenic acid; XA*T, xanthurenic acid 
interaction with time.
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not conclude that the associations with cognition are con-
fined to patients with dementia, due to the absence of an age-
matched longitudinal control group. Our previous study on 
community-dwelling older adults indeed found a similar 
association between Kyn and cognitive function.21 
Kynurenines in the brain may mostly be derived from circu-
lating kynurenines with Kyn as the main precursor.3 Still, 
synthesis of the potentially neuroprotective KA is confined to 
astrocytes, whereas the potentially neurotoxic QA is synthe-
sized in microglia.3 Thus, our assessment of kynurenines in 
dementia is incomplete without measurements of CSF and/
or brain samples.
In summary, circulating Kyn concentrations around the 
mean level may be beneficial for cognitive function in patients 
with dementia. Serum Kyn concentrations which diverge from 
the mean in either direction (higher or lower) may be associ-
ated with poorer global cognitive function. We observed an 
association of KA and KKR with neuropsychiatric symptoms, 
which adds to existing literature suggesting a role of kynure-
nines in mental health.3
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